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Abstract 
 
Some types of cancers are more difficult to treat than others, and to date, there is no general 
accepted standard approach how to treat pancreatic cancer.  The aim of this project was to 
construct an immunotoxin with an affinity towards pancreatic cancer cells.  The idea is that 
the coupling of a scFv antibody to a toxin will improve tumor selectivity of a drug that is too 
toxic to be used on its own, as well as to confer cell killing power to the scFv antibody that is 
tumor-specific but not sufficiently cytotoxic.  
A naïve phage scFv library was screened with the CBASTM method and the tumor cell line 
specific polyclonal mixture, obtained from the panning, was cloned into the cloning vector 
pHOG21 and expressed in E. coli.  6000 clones were randomly picked and after 
characterization and DNA fingerprinting, 96 promising clones where chosen for further 
characterization.  Of these 96 clones, 85 % were obtained from panning at 37 ˚C, supporting 
the hypothesis that the CBASTM method preferentially selects for internalizing antibodies.  
Finally one pancreatic carcinoma specific scFv, B1-J21, acquired from panning at 37 ˚C, was 
selected to serve as a delivery vehicle for the toxin in the immunotoxin complex. 
6-Alkenylpurines have been proven to show cytotoxic activity against some human cancer 
cells and were chosen to serve as a model for the toxin that was to be synthesized.  In order to 
be able to couple the toxin to the scFv via the SPDP linker, a free amino group on the toxin 
was needed and it was therefore decided that 9-(4-aminobenzyl)-2-chloro-6-E-styryl-9H-
purine (7) would be employed as a toxin in these studies and was to be synthesized in 2 
slightly different ways.  After N-alkylation of 2,6-dichloropurine (2) with 2 different benzyl 
chlorides, 4-nitrobenzyl chloride (8) and 4-acetamidebenzyl chloride (9), the corresponding 
products 3a and 4a were subjected to Stille couplings in order to introduce a styryl group in 
the purine 6-position.  Despite the fact that during the coupling reactions only half of the 
recommended amount of the tin reagent was used, (E)-N-{4-[(2-chloro-6-trans-styryl-9H-
purin-9-yl)methyl]phenyl}acetamide (5) was isolated and purified in 41 % yield.
 iii 
 
Under the recommended conditions, the compound with an acetamide group para substituted 
in the benzyl group at the purine 9-position 4a, seems to be much more reactive in the applied 
cross-coupling reaction than the corresponding compound 3a with a nitro group in the para 
position of the benzyl group at the purine 9-position. 
With only step left in the synthesis of the toxin 7, the hydrolyzation of the acetamide group of 
compound 5 to the amino group, the time intended for this master thesis came to an end.  If 
the conversion of compound 3a to (E)-2-chloro-9-(4-nitrobenzyl)-6-trans-styryl-9H-purine (6) 
had been successful, the plan was to reduce the nitro group in the purine 9-position to the 
required amino group. 
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1. Introduction 
 
1.1 Cancer  
 
1.1.1 General introduction 
 
In the human body cells are constantly dividing and multiplying, and our genes carefully 
control this process. If cells begin to divide unnecessarily, they will form an excess tissue 
known as a tumor. In many cases tumors are benign, meaning that they are not cancerous, but 
if an abnormal cell begins to divide it eventually forms a cancerous, or malignant 
tumor. Malignant tumors grow quite rapidly and can invade nearby organs and tissues. 
Cancerous cells can also travel through the blood- or lymphostream to other regions of the 
body and therefore spread the cancer from its original site, a process that is known as 
metastasis.1a 
 
1.1.2 Different types of cancer therapy 
 
Cancer is a disease that can strike anyone, at any age, and it can affect every organ in the 
body.  Each year there are tens of millions of people diagnosed with cancer worldwide.2 Many 
different types of cancer exist and therefore different needs of treatment, depending on the 
cancer type, location, size, and the age and health of the patient.  The three major types of 
cancer treatment, the so-called classical therapeutics, include surgery, radiation therapy, and 
chemotherapy and all these modalities can be used either alone or in combination with each 
other.3 But even though these treatments have helped to fight some cancers they have many 
disadvantages, including severe side effects because their mode of action is usually not 
restricted to the malignant tissue, but acts also on healthy normal tissue.  With increasing 
focus on this deadly disease there are constantly new discoveries and fortunately, the death 
rates have been declining in recent years.  But we still face many difficulties and some types 
of cancers are more difficult to manage or even cure than others.  Pancreatic cancer, in 
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special, is one of the most lethal cancers with an overall-5 years-survival rate of less than 
5%.4 
 
1.1.3 Pancreatic cancer 
 
The pancreas is a gland located in the abdomen and is surrounded by the stomach, small 
intestine, liver and spleen (Figure 1).  In an adult it is about 15 cm long and has a flat pear-
liked shape. 
 
Figure 1: A figure of the human pancreas5  
 
It is two main functions are the production of enzymes that help in digestion (exocrine 
function), and the production of the hormones, insulin and glucagon, which maintain the 
proper level of sugar in the blood (endocrine function).4 There are two different types of 
pancreatic cancer that exist.  The majority of pancreatic tumors, which involves the cells that 
line the pancreatic duct, are exocrine tumors known as adenocarcinomas.  Figure 2 is from 
immunohistochemistry (IHC) and shows an example of an exocrine tumor in the pancreas.  A 
less common type of pancreatic tumors is known as endocrine tumor and origins in the islet 
cells of the pancreas.   
  
Figure 2
 
Pancreatic cancer is the second most common tumor of the digestive system in the Western 
World with clearly increasing incidence
One of the reasons why this type of 
quite a small organ and is deeply seated in the abdomen.  It is therefore not easily accessible 
and diagnosis can be somewhat 
years of age with a male : female ratio of 2 : 1.  
resectable, and patients must be treated with adjuvant therapy
is given after the primary treatment to increase the chances of a cure.  H
therapy remains palliative.  To date, there is no generally accepted standard approach to treat 
patients with pancreatic cancer in the adjuvant setting. This controversy d
studies, each of which is burdened with its own limitations.  Standards of care also vary 
depending on European or North American practice.  In North America, chemo
(simultaneous chemotherapy and radiation therapy)
considered the optimal therapy, while chemotherapy alone is th
Future developments of adjuvant therapy have raised the issue of second
especially after the establishment of gemcitabine 
in which it achieves a significant clinical benefit response.  
gemcitabine under investigation include the antimetabolite 5
topoisomerase-I inhibitor irinotecan and th
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: Human pancreatic cancer6  
 and an overall-5-years-survival rate of less than 5 %
cancer is so difficult to manage is that the pancreas is 
lengthy.  More than 80% of cases occur between 60 and 80 
Only few percent of all pancreatic tumors are
7
, a postoperative treatment that 
owever, adjuvant 
erives from several 
 followed by only chemotherapy is 
e current standard in Europe.
-
 as a first-line standard treatment approach, 
Other combination partners with 
-fluorouracil (5
e taxane docetaxel (Figure 3). 
 
.
4
  
 
-radiotherapy 
8
  
line therapy, 
-FU), the 
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Figure 3: Gemcitabine and combination partners 
 
Both Gemcitabine and 5-FU are nucleoside analogs or analogs of pyrimidines to be precise, 
and are used worldwide in various carcinomas, including Norway.  Their mode of action as 
drugs is by replacing one of the building blocks of nucleic acids in DNA synthesis, a process 
that arrests tumor growth as new nucleosides cannot be attached to the defective nucleoside 
which results in apoptosis (cellular suicide).1b  Irinotecan and Docetaxel are also registrated as 
drugs in Norway and both are chemotherapy agents.  The inhibition of the enzyme 
topoisomerase-I by Irinotecan eventually leads to inhibition of both DNA replication and 
transcription and therefore to cell death.1c Docetaxel is a antimitotic acent and has been used 
as an anticancer agent since mid-1990s.1d It acts by binding to tubulin and interferes with the 
formation of the mitotic spindle and therefore prevents cellular mitosis and causes cellular 
death.      
Combined-modality approaches with gemcitabine and radiation are also under active 
investigation.9 Only around 15% of pancreatic tumors are resectable10 and the morbidity and 
mortality after such surgeries are not insignificant and therefore the overall prognosis after 
resection remains poor.  Despite all of these disadvantages, surgery currently remains the only 
hope of cure for the patient.  Current surgical issues have focused on ways to improve clinical 
outcomes following potentially curative resections but survival and quality-of-life remain 
poor.  Postoperative chemotherapy is widely used and supposed to prolong survival.11 
Pancreatic disease is similar to other gastrointestinal malignancies in which 
radioimmunolocalization (RIL) has been evaluated.  RIL provides the possibility to visualize 
the tumor in vivo by using radio-labeled antibodies which bind to tumor-associated antigens 
that are present on the surface of malignant cells.12  Currently, monoclonal antibodies are 
sometimes used for diagnosis of pancreatic cancer, follow up and monitoring. The expression 
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of a small number of antigens has been demonstrated to enable some differentiation between 
pancreatic cancer and principally chronic pancreatitis. To date, the cross-reactivity of 
antibodies has resulted in only limited specificity, but it does appear that at least some are 
appropriate target antigens.13 
Due to the unmet medical need, and the clear implications of potential effectiveness of 
antibodies for the adjuvant therapy of pancreas carcinoma, such antibodies are very 
interesting objects for both academic and industrial research.  A largely growing field in the 
development of cancer treatment, involving the use of antibodies, is a biological therapy 
called immunotherapy. 
 
1.2 Immunotherapy 
 
1.2.1 General introduction 
 
This approach to cancer therapy uses the body's own natural defenses, including antibodies, to 
fight the cancer. Antibodies are proteins of the type that is called immunoglobulin (Ig) and 
consists of four polypeptides, two identical heavy chains and two identical light chains, joined 
to form a Y shaped molecule.  A full size Ig antibody of the IgG subtype can be seen in Figure 
4.  Antibodies are produced in B-lymphocytes and they defend the body against toxins and 
microorganisms that enter the bloodstream.  Each B-lymphocyte has its own unique antibody, 
which it makes copies of, and displays it on its outer surface (called B-cell receptor).14a 
Immunotherapy is tumor cell directed, and specifically lethal to malignant cells and therefore 
less toxic to normal tissues.  Each chain of an antibody is composed of structural domains, 
called Ig domains, which are classified into either variable or constant domains, according to 
their size and function. 
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Figure 4: Schematic representation of an IgG antibody and its domain structure 
 
The constant region is identical in all antibodies of the same isotype, but differs in antibodies 
of different isotypes, while the variable region in antibodies produced by different B cells 
differs but is the same for all antibodies produced by a single B cell. The amino acid sequence 
at the tips of the Y varies greatly among different antibodies and is composed of 110-130 
amino acids.15 Antibodies bind to specific areas on the surface of cells known as antigens, 
which are usually proteins or polysaccharides.  The specific amino acid sequence in the 
variable region determines the antibody's specificity against a single antigen.  The unique part 
of the antigen that is recognized by a specific antibody is called an epitope.14a Each antibody 
binds its epitope in a highly specific interaction, called induced fit, which allows it to identify 
and bind only its unique antigen in the midst of the millions of different molecules.  After 
binding, the antibody eliminates the antigen.  The variable region is further subdivided into 
framework (FR) and three sets of hypervariable (HV) regions.  The highly variable amino 
acids in the HV region directly contact a portion of the antigen's surface and because of that, 
the HV region is also sometimes referred to as complementarity determining regions, or 
CDRs.  The FR regions have more stable amino acids sequences and hold the HV regions in 
position to contact the antigen. The constant region of antibodies, around 450-550 amino 
acids, divides them into five major classes, IgM, IgG, IgA, IgD, and IgE, and defines their 
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immune functions and their mechanism to destroy the antigen.  From a biotechnology 
perspective, the IgG subtype is the most important one.15 
When the antibody is treated with a protease, an enzyme that hydrolyzes the peptide bond 
between the amino acids, it can be cleaved into biologically active fragments.  Fragment 
antigen binding region (Fab) is composed of one constant and one variable domain from each 
heavy and light chain of the antibody and contains the site that binds the antigen.  Fragment, 
crystallizable region (Fc) is composed of two heavy chains that only contain constant 
domains, and this portion of the antibody ensures that each antibody generates an appropriate 
immune response for a given antigen.  In addition the Fc region is associated with serum half-
life of the antibody, which is only few hours for an antibody fragment.  In contrast, some full 
size antibodies have a half-life up-to 3 weeks.15 
Modern cancer therapy has harnessed and enhanced the body's natural potency to defend itself 
against malignant tumor and along with the development of hybridoma technology, the 
designing and use of so called monoclonal antibodies, has become a powerful weapon. 
 
1.2.2 Monoclonal antibodies 
 
The first generation of monoclonal antibodies has been described for the first time in 1975 by 
Köhler and Milstein.  This work is considered to be one of the most important discoveries in 
biomedical research in the past century3 and has been rewarded with the Nobel Price in 1984.  
Köhler and Milstein were able to isolate and generate unlimited quantities of a pure 
monoclonal antibody from among the mixture of small amounts of many different antibodies 
produced in an immune response.16 To do so, they generated hybridoma cells by fusing B 
cells from a mouse that had been immunized with a particular antigen, to mouse myeloma 
cells (bone-marrow-cancer cells).14a The myeloma cells enable hybridomas to grow well in 
cell-culture and divide indefinitely, while the B cells confer antibody production capability.  
By using this method, individual hybridomas producing the desired antibody from a single 
lymphocyte could then be selected for large-scale culture and monoclonal antibody 
production, which makes them amenable to industrial production.  In the initial phase of using 
such monoclonal antibodies for therapeutic purposes in humans, the results were 
disappointing.15 This was mainly due to the fact that, being murine antibodies derived solely 
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from mouse sequences, they elicit human anti-mouse antibody (HAMA) immune responses.  
The human immune system rapidly inactivates them and therefore prevents them from 
providing long-term therapeutic benefits.  Being xenogeneic (genetically foreign) the recipient 
might mount a specific immune response against the antibody that can be very strong, leading 
even to septic shock.  Therefore, a general clinical use of murine monoclonal antibodies in 
man has broadly failed.     
 
1.2.3 Recombinant antibodies 
 
One approach to solve the problem of immunogenicity of monoclonal antibodies is by 
generating human hybridomas.  But it turned out that these cell lines are often unstable and in 
many cases poor producers, making the production of large amounts of antibodies technically 
very difficult and economically challenging.17 Another and more advanced approach is to 
create recombinant antibodies.  This can be achieved in different ways.  (A) One is by 
engineering mouse/human-hybrid antibodies that still bind the antigen, but are less likely to 
be immunogenic.  Looking at the genetic background, murine/human recombinant antibodies 
can be of two types: (i) chimeric, a mouse/human mixture that consists of the rodent-derived 
variable regions fused to human constant regions, (ii) humanized, a mouse/human mixture 
that is generated by grafting only the CDRs of xenogenic antibodies onto human framework 
and constant regions.  (B) Another is by engineering completely human antibodies in which 
the exposed residues of a murine immunoglobulin in the framework regions that differ from 
those usually found in human antibodies have been replaced.20 By replacing much of the 
rodent-derived sequence of an antibody with sequences derived from human immunoglobulin, 
it is possible to generate antibodies that are much less immunogenic than their rodent 
counterparts. 
The fact that recombinant antibodies are capable of highly specific interaction and therefore 
can kill a malignant cell without harming healthy neighboring cells is not their only 
advantage.  They also have the ability to penetrate through cancer masses, not only kill the 
cells that are on the surface of the tumor.  The ideal anticancer antibody has to be specific and 
reach the tumor sites in the parts of the human body where the primary and metastatic tumors 
are located and at the same time never target the great majority of growing and differentiating 
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normal cells.3 However, complete antibody molecules are quite large and due to their size, 
they might have limited in situ access to some tumor cells.  Such inadequate and non-uniform 
localization in solid tumors is a key factor limiting their use for treatment of solid tumor 
masses.  
 
1.2.4 Single chain Fv (scFv) 
 
These limitations of full size antibodies as therapeutic agents have been addressed by 
genetically engineering smaller molecules.  In 1988 the production of the Fab and the Fv 
fragments of antibodies were achieved in myeloma cells and the bacterium Escherichia coli 
(E. coli).3 Besides those two fragments, the variable region (V) genes of both the heavy (H) 
and the light (L) chain of an antibody can also be genetically linked to peptides and then 
expressed in E. coli.  This single chain of Fv, seen in Figure 5, is called single chain variable 
fragment (scFv) and is the smallest fragment available that carries the whole antigen-binding 
site of the antibody and it is greatly stabilized by this short peptide linker.  
 
NH2
COOH
Peptide linker
VH VL
S
S
S
S
  
  Figure 5: Single-chain Fv (scFv) 
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With the length of approximately 3.5 nm, the peptide linker is connected to the carboxy 
terminus of one domain and the amino terminus of the other, covalently connecting them 
together and generating a quite stable single chain.17 Functional scFv molecules are composed 
of only these heavy and light chain variable regions and have a molecular size that is only 1/6 
of the original Ig antibody.   Due to their small sizes, scFv antibodies can more easily access 
cells and tumors than full size antibodies, which results in improved tumor penetration.18 
Their size also makes their large-scale production much easier: usually prokaryotic expression 
systems are used instead of laborious, slow growing and expensive eukaryotic systems which 
are needed for whole Ig antibody production.  Another advantage that scFvs have over 
monoclonal antibodies due to their sheer smaller size is that they are much less immunogenic, 
even when comprising xenogeneic regions as is chimeric and humanized scFvs.  Just as is 
with full size antibodies, antibody fragments can become more “humanized” by replacing 
many of the rodent derived sequence with sequences derived from human antibodies.  
Because the antigen binding site of the antibody is localized within the variable regions, 
“humanizing” the Fv regions can be done without a loss of function (and the same is true for 
Fabs or whole antibodies of course).17 Beside obtaining scFv fragments from existing 
monoclonal antibodies, they can be derived from naïve, immune, semi-synthetic or fully 
synthetic libraries.19 Naïve libraries are derived from human blood or tissue samples from 
normal donors in contrast to immune libraries where the blood/tissue samples are collected 
from patients.  Semi-synthetic and synthetic libraries are constructed by introducing 
randomized CDR-cassettes in human Fv frameworks.  To obtain scFv fragments with an 
affinity towards a specific target from these libraries, a various screening techniques are 
applied such as phage display, hybridoma technology or immunization.20   
In addition there are few methods for the construction of a recombinant scFv, for example by 
using colony screening and antigen coated membranes.  That way can single bacterial 
colonies, that express the antigen specific antibody fragments, easily be identified.  Even 
though bacteria cannot be used to assembly whole glycosylated antibodies, bacterial systems 
are very suitable hosts for the production of antibody fragments, since they lack the 
glycosylated Fc moiety.17 At present scFv antibodies are not widely used as therapeutics 
because they are rapidly cleared from the serum.21 However, because of their simplicity and 
their ease of manipulation they offer a number of advantages, including their ability to be 
used as immunotoxins. 
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1.2.5 Immunotoxins 
 
When trying to increase the effectiveness of an anticancer drug even further, recombinant 
immunotoxins were discovered.  They are composed of an antibody part, e.g. recombinant 
scFv fragments coupled to a potent toxin.18 Many toxins that are used are highly cytotoxic and 
since they do not distinguish between cancer cells and normal cells, they display severe side-
effects (the well-known side effects of cancer chemotherapy, for example).  On the other 
hand, when they are coupled to scFv fragments the specificity of the antibody guides the toxin 
directly to cancer cells without recognizing or (theoretically) having any influence on normal 
cells.  The antibody binds to its surface antigen and the antibody-antigen complex is then 
internalized.18,22 Because the scFv is a protein with a quite short intracellular half life, once 
inside the cell the scFv complex is broken down, usually in endosomes.  This causes the 
release of the toxin which translocates into the cytosol where it e.g. inhibits a critical cell 
function and causes cell death.  A quickly internalizing scFv antibody is important, and in fact 
essential, for the development of an effective immunotoxin, or else substantial amounts of the 
toxin would be released already extracellularly and left circulating in the body.  Instead a 
quickly internalizing scFv acts as a powerful delivery vehicle and transports the toxin inside 
the cell where it can perform its function.  It is important that the linker that couples the toxin 
to the scFv biological is stable and is not cleaved in the blood or serum.  A quite few 
immunotoxins have made it into clinical trials23,24 and few of them, like Gemtuzumab 
ozogamicin (marked as Mylotarg) has been approved by the US Food and Drug 
Administration (FDA) for therapy of acute myloid leukemia.14b  But the need for more tumor 
entity-specific and also more effective immunotoxins is still great, and the progress of these 
immunotherapeutic agents into clinical applications is comparably slow to date.  Each one has 
to undergo extensive preclinical development where its toxicity and efficacy, both in vitro and 
in vivo, has to be tested.  The major clinically limitations of immunotoxins today are 
immunogenicity, toxicity, and instability.  The ideal immunotoxin should be non-
immunogenic and cause minimal toxicity to normal tissue.  At the same time they should have 
access to, and the potency to kill tumor cells and their progenitors in both solid and 
disseminated tumors.25 To be able to fulfill these requirements the antibody part of the 
immunotoxin has to have high affinity to, and only to, its target antibody. If such an antibody 
or antibody fragment is to be obtained from an antibody library, a powerful screening method 
is needed. 
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1.3 Antibody discovering – methods 
 
1.3.1 Phage display 
 
Phage-display was first described by George Smith in 1985 and has now become one of the 
most widely used library methodologies in the search for new drugs amongst hundreds of 
thousands of components.26 Combining the generation of billions of different peptides or 
proteins from large libraries with a fast screening or selection procedure, this method offers a 
powerful route for the identification of most interesting lead candidates. 
Bacteriophages (phages) are viruses that infect bacteria and are completely depended upon the 
host organism to propagate.27a As soon as the phage DNA is inside the bacterial cell the 
phages subvert the host’s cellular processes to serve the needs of the virus. 
Phage-display is based on the use of a filamentous phage20, a bacteriophage that lives on 
E.coli and the whole phage display cycle can be seen in Figure 6. 
 
 
 
Figure 6: The phage display cycle 
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During this cycle, library of proteins, for example antibody library in the Fab or ScFv format, 
is fused to the pIII coat protein gene of the filamentous bacteriophage M1322,28 (called helper 
phage). The M13 phage genome is a plasmid, circular single-stranded DNA molecule, and it 
is packaged into phage particles.  This plasmid, encoding a fusion of an antibody fragment 
with pIII, replicates and produces the fusion protein independently from the phage genome.  
Since it carries the morphogenetic signal of phage, it is called a phagemid.14c During the 
expression of the DNA, the phagemid is incorporated into new phage particles that are 
assembled in the bacterium.  After expression of the fusion product and its subsequent 
incorporation into the mature phage coat, the fusion antibody fragment is presented on the 
phage surface while its genetic material resides within the phage particle.  By locating the 
antibody gene on the phagemid and uncoupling it from the phage cycle by stopping its 
replication and expression, genetic stability and propagation of the antibody library is greatly 
facilitated.14c 
Phages that display an antibody specific for an antigen can easily be enriched by a process 
known as panning.  Selective adsorption of antibody-displaying phages of interest onto 
immobilized antigen and elution of the bound phages are the main steps of the panning 
procedure.  Library panning is a good way to selectively enrich the appropriate variable 
heavy- and light chain combination from a library of scFv phages.  The phages are then 
amplified through infection of E. coli cells.15 During the phage cycle, non-adherent phages are 
simply washed away.  Finally the antibodies that have the desired biological properties are 
selected by exploiting their desired affinity of binding.  The first class of proteins to be 
successfully displayed on the surface of phages were antibodies.29 
Phage display has now become one of the most successful methods for the screening and 
selection of antibodies to defined target antigens from large phage antibody libraries.23 The 
use of display vectors and in vitro selection technologies is a rapidly developing field and 
today, it is possible to synthesize tailor-made antibodies and select those having the desired 
affinity of binding.  Many methods are applied as a selection method depending on the target 
and in fact any method that separated those clones that bind to the target from those that do 
not bind, can be utilized as a selection method. 
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1.3.2 Different types of selection methods 
 
The most promising approach for the development of targeted therapies is probing the 
diversity of cell surfaces and identifying binding partners for cell surface molecules specific 
for certain cell types or disease-related states.  However, the identification of such binding 
partners is often challenging experiments. 
Conventional methods for the identification of binding partners for cell surface molecules are 
based on the incubation of cells in suspension or culture with complex phage display scFv 
libraries followed by several washings and acid or alkaline elution of bound phages.  
Irrelevant binding partners are then removed by negative panning on irrelevant cell 
types.30,31,32  A more recently developed and more high-throughput method is the screening of 
cells with a phage display library after immobilization of the cells onto nitrocellulose 
membranes.33  
An alternative and time saving approach to the conventional approach for the screening, 
selection and sorting of cell surface binding peptides using a phage display library has been 
described by Giordano et al., and is termed the BRASIL method.34 This method is based on a 
single step organic phase separation of free and cell bound phages which has the advantage 
that the washing steps essential to the conventional method, which are labor intensive, 
inefficient and result in cells and potential ligands being lost, are avoided. 
Affitech AS has developed a method called Cell-Based antibody Selection (CBASTM) for 
selection of membrane protein-specific antibodies.35 CBASTM is based on the single step 
organic phase separation and has shown significant improvement over the conventional 
washing and elution method described above.  
 
1.3.3 CBASTM 
 
The CBASTM technology is a method for the rapid isolation of specific recombinant 
antibodies directed against antigens on whole living cells.  It enables the generation of fully 
human, scFv antibodies that recognize antigens in their natural configuration, with proper 
three dimensional folding and appropriate display in the cell membrane.  In addition, there is a 
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hypothesis that the CBASTM method preferentially selects for internalizing antigen/antibody 
pairs.  The procedure consists of screening a human scFv antibody library against various 
mammalian cell types by using phage display, preceded by a preliminary step to remove non-
specific binders.  To obtain high affinity binders, the cycle can be reinitiated for as many 
serial rounds as needed.  Following initial selection, the products are assessed by a polyclonal 
phage ELISA (enzyme-linked immunosorbent assay) (Chapter 5.1.2, p. 59) and phagemids 
from the positive pools are cloned into an expression vector.  The CBASTM method offers the 
possibility to rapidly and efficiently identify new antigenic markers for cancer and other 
pathological conditions.  
 
1.4 The aim of the project 
 
1.4.1 General 
 
The aim of this project was to synthesize a novel immunotoxin with specific affinity towards 
pancreatic cancer cells.  This was to be done by identifying tissue-specific scFv antibody that 
is selectively expressed on the surface of these cells.  The toxin 7 in Scheme 3 (p. 19) was to 
be synthesized in 2 slightly different ways to serve as a toxin in the immunotoxin complex.  
After coupling the toxin to the scFv antibody they would form a novel cancer specific 
immunotoxin directed against pancreatic cancer cells that would finally be tested both in vitro 
and in vivo (in a mouse model).  
 
1.4.2 Selection of toxin 
 
It has been reported that some purine derivatives are potential anticancer drugs.  6-Alkynyl- 
and 6-alkenylpurines have been screened for cytotoxic activity against a human chronic 
myelogenous leukemia cell line and their toxicity compared to known anticancer drugs.36 The 
compound 1 shown in Figure 7 was one of the most active cytotoxic compound from these 
studies, displaying cytotoxicity comparable to, or better than, the known anticancer drugs 6-
mercaptopurine and fludarabine. 
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Figure 7: (E)-9-Benzyl-2-chloro-6-styryl-9H-purine (1)  
 
Because of these promising results, it was really interesting to see if compound 1 in Figure 7 
could be used in the immunotoxin complex, serving as a toxin to disrupt the growth of 
pancreatic cancer cells.  The activity of the compound was confirmed by toxicity studies 
where the cytotoxicity was tested on cell lines from different tissue origins.37  
To be able to couple this compound to the scFv antibody, there are a few things that need to 
be considered.  There has to be a functional group in the molecule which can be used to 
couple to the linker, without affecting the cytotoxic activity of the compound.  Although it has 
not been proven how this compound acts as cytostaticum, the screening described by Bråthe 
et al shows that an alkenyl or alkynyl group at C-6 is required for such an activity.  Such 
compounds are prone to nucleophilic attack36 and it is not unlikely that such an attack to the 
alkenyl group is the mode of action for this compound as cytostatica.  The screening also 
shows that an electron withdrawing group (EWG), like the chlorine, in the purine 2-position 
enhances cytotoxic activity, probably by making the alkenyl group more electrophilic 
(Scheme 1).  
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Scheme 1: The hypothetical mode of action of the toxin as cytostatica 
 
The linker should therefore not be coupled to the molecule in either of these positions.  To 
avoid interference with the bioactivity of the compound it was therefore decided to couple an 
amino group in the p-position of the benzyl group at the N-9 of the purine. 
 
1.4.3 Selection of linker 
 
It was believed that the amino group of both the scFv antibody and the toxin could be reacted 
with a heterobifunctional linker called SPDP (N-succinimidyl 3-[2-pyridyldithio]propionate) 
to form a carboxamide bond.38 SPDP is to date one of the most widely used cross-linker for 
generating antibody-toxin conjugates and the reaction is shown in Scheme 2.  After 
generating the carboxamide bond, the introduced 2-pyridyldisulfide group on the scFv is then 
reduced by DTT (dithiothreitol) to generate a free thiol.  When the scFv fragment and the 
toxin are mixed together in a 1 : 1 ratio, the reduced thiol nucleophilically displaces pyridine-
2-thione from the toxin, resulting in the immunotoxin conjugate.   
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Scheme 2: Coupling of the toxin to the scFv with SPDP 
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1.4.4 Synthetic strategy for preparation of the toxin 
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Scheme 3: Synthetic strategy plan for 9-(4-aminobenzyl)-2-chloro-6-E-styryl-9H-purine 
(7) 
 
The synthetic strategy plan for the toxin to be employed in these studies was to N-alkylate 
(Scheme 3) the 2,6-dichloropurine (2) with 2 different benzyl chlorides to obtain the N-9 
nitro- and acetamide purines (3a and 4a).  Compounds 3a and 4a were then subjected to Stille 
couplings to introduce the styryl group in the purine 6-position.  The acetamide group of 
compound 5 was then to be hydrolyzed to obtain the amino group while the nitro group of 
compound 6 was intended to be reduced to acquire the toxin 7. 
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1.5 Purines 
 
1.5.1 General introduction 
 
Purine is an unique heterocyclic aromatic system and was first prepared in 1899 by the 
German chemist Emil Fischer.  He reduced 2,6-diiodopurine with zinc dust and recovered a 
colorless, crystalline weak base.39,40 The structure can be seen in Figure 8 and consists of an 
electron-poor, 6-membered pyrimidine ring and an electron-rich, 5-membered imidazole ring, 
each ring containing two heteroatoms. 
 
Figure 8: 9H-Purine 
 
The numbering of the purine ring system does not follow standard rules but is anomalous for 
historical reasons.41,42  There are two different numbering systems that are used for purine;  
the CAS nomenclature which uses the lowest numbered position for the indicated hydrogen in 
the purine ring system, and the more widely used IUPAC nomenclature where the 9H-isomer 
is named purine without specifying the indicated hydrogen.  When discussing purine herein, 
the IUPAC convention will be followed. 
Purines can exist in four NH-tautomeric forms that differ by the site of attachment of the 
proton at the nitrogen (Figure 9). 
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Figure 9: Purine tautomers 
 
Only the 7H- and the 9H-tautomers are detected in solution and they are far more stable than 
the 1H- and the 3H-tautomers.  The general term, purines, also refers to substituted purines as 
well as their tautomers.  Purine itself is a relatively weak base, with a pKa of 3.39.41 The 
reactions of purines exemplify the interplay of the constituent imidazole (pKa = 6.99) and 
pyrimidine rings (pKa = 1.31), where the pyrimidine contributes an electron-poor and the 
imidazole an electron-rich unit to the structure and chemistry.  Electron-withdrawing groups 
on the purine decrease the basicity while electron-donating groups increase basicity.  Purines 
are susceptible to reactions with both electrophiles and nucleophiles. 
 
1.5.2 Bioactive purines 
 
Uric acid (Figure 10) is the end product of purine catabolism in man and was the first purine 
isolated, in 1776.39 Although purine itself has not been found in nature, substituted purines 
exist naturally in an enormous amount and it is in fact the most widely distributed nitrogen-
containing heterocycle in nature.43 When combined with ribose or deoxyribose, as nucleosides 
or nucleotides, purine bases form polymers of ribonucleic acid (RNA) and 2’-
deoxyribonucleic acid (DNA).  Not only are the purines constituents in 50% of the genetic 
material (DNA), they are biochemically significant components in a number of other 
important biomolecules.  A few essential ones are; adenosine-5’-triphosphate (ATP) which is 
the storage of energy in cells, adenosine 3’,5’-cyclic phosphate (cAMP) controls the 
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potassium level of the cell, the activation of protein kinases, as well as transcription and other 
metabolic processes, coenzyme A (CoA) possesses a high group-transfer potential for acetyl 
groups, and nicotinamide adenine dinucleotide (NAD) and flavin adenine dinucleotide (FAD) 
are involved in cellular redox processes.40 In addition, monomeric nucleosides and 
nucleotides also act directly as neurotransmitters and hormones.41 Many derivative 
compounds of purine are also of significance importance in a number of areas of medicinal 
chemistry and several of them can be found naturally; Theophylline occurs with caffeine in 
tea leaves and is a powerful diuretic and has clinically been used in the treatment of asthma.  
The major purine constituent of the coffee bean is caffeine.  It also occurs in tea leaves and 
acts as a cardiac and respiratory stimulant.40 
 
     
Figure 10: Some of the common naturally occurring oxopurines 
 
Just as substituted purines are many, their effects are diverse; adenine and xanthine (Figure 
11) act as agonists or antagonists of adenosine receptors, which play an important role in 
chemical signaling.41 Some 8-oxoadenine derivatives, which have been isolated from different 
natural sources, show antibiotic properties.  The cytokinines are plant growth substances and 
promote cell division.  Kinetine was the first cytokinine that was examined in detail and has 
been commercially used to keep green vegetables for extended periods.40 
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Figure 11: Adenine, xanthine, 8-oxoadenine, kinetine 
 
1.5.3 Purine-containing drugs 
 
Because of the wide range of biological activity of purines, they are essential for any form of 
life and the appreciation of the importance of purines in medicine is always becoming clearer.  
Our synthetic group at The University of Oslo has synthesized many different modified 
purines that have proven to have interesting biological properties, such as antimycobacterial 
effect44, cytokinin activity45 and cytoxicity against mammalian cells.36 These promising 
results from our group are of great interest as there is an urgent need for new treatment of 
many kinds of diseases.  Despite major breakthroughs in many areas of modern medicine, a 
successful treatment of cancer remains a challenge at the beginning of the 21st century (see 
more about cancer in chapter 1.1).  Anticancer drugs are often referred to as cytotoxic or anti-
metabolites41 and generally act by disrupting the growth of cells and therefore oppose the 
excessive and abnormal growth.  Anti-metabolites are often chemically similar to the natural 
metabolite.  Many purines and their analogs exhibit anti-metabolite activity,46 with the 
previously described 5-FU (Figure 3, p. 4) as an example.1b 
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1.6 Toxin synthesis - methods 
 
1.6.1 N-alkylation 
 
Purines that have a free NH are commonly N-alkylated under basic condition in a polar 
solvent (DMSO, DMF) by generating a purine anion.40  The reaction usually occurs in the 
imidazole ring via an N-anion and often results in a mixture of N-7/N-9 isomers.  Typical 
alkylating agents are for example alkyl halides, methanesulfonates, or 4-toluenesulfonates.  
The selectivity of the reaction depends on various factors such as; the solvent medium, the 
type of the base that is used, the reactant concentration and the structural nature of the 
alkylating reagent.  When halide derivatives are used as alkylating agents, a change of solvent 
from dimethyl sulfoxide (DMSO) to dimethyl formamide (DMF) can in some cases drive the 
reaction towards the N-9 alkylating product.  This can also be accomplished by the presence 
of bulky substituents at C-641 (Scheme 4). 
 
 
Scheme 4: N-Alkylation reaction of purine driven towards the N-9 alkylating product 
 
1.6.2 The Stille reaction 
 
The Stille reaction was discovered by John K. Stille and David Milstein in 1977.47 This 
widely used cross-coupling reaction is used to couple an organotin compound with an organic 
halide, generating a new C-C bond, and is catalyzed by palladium.  The general reaction can 
be seen in Scheme 5.  Although it is nowadays considered a standard method in organic 
synthesis, modifications and variants of the Stille reaction have opened a multitude of new 
and highly attractive synthetic possibilities and it continues to be exploited industrially, 
especially for pharmaceuticals.48 
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Scheme 5: The Stille reaction 
 
This is a versatile reaction and except from alkyl groups which are relatively un-reactive, 
there are very few limitations on what R group can be used.  The main drawback is the 
toxicity of the tin compounds used, and their low polarity, which makes them poorly soluble 
in water.49 A tributylstannyl compound is often used as the organic tin compound, although 
trimethylstannyl is more reactive, it is also about 1000 times more toxic.  The palladium 
catalyst used in the Stille reaction can be oxidized by the oxygen in the atmosphere and these 
reactions are therefore usually performed under inert atmosphere using dehydrated and 
degassed solvent.  Oxidized palladium promotes dimer formation of organic stannyl 
compounds which leads to decrease in the yield of the desired cross coupling reaction.50   
One of the major advances in synthetic chemistry in the last quarter of the twentieth century 
was the use of palladium(0) catalysts for the construction of new C-C and C-hetero bonds to 
aromatic molecules.41 Palladium-catalyzed reactions are widely used among the most 
important transformations and work equally well for both carbocyclic and heterocyclic 
systems.  The typical palladium-catalyzed reactions can be seen in Scheme 6.   
 
 
Scheme 6: Typical palladium-catalyzed reactions 
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One of the main advantages of this type of reaction is that normally un-reactive aromatic-type 
halogens can be replaced under relatively mild conditions.  Another important feature to note 
is that these reactions generally do not interfere with, or are jeopardized by, the presence of 
most other functional groups.  In most of these reactions, the catalytic amount of the 
palladium complex used is 1 – 5 %.41 
The reaction mechanism of the Stille reaction has been well studied50 and is based on 3 
reaction steps: (i) oxidative addition, (ii) transmetalation, and (iii) reductive elimination 
(Scheme 7).   
 
1
Pd0Ln
R1 Pd''Lm X
4
R1 Pd''Lm R2
R1 X
32
7
R1 R2
8
R2SnBu3
56
XSnBu3
Pd (II)
(i)
(ii)
(iii)
 
Scheme 7: The catalytic cycle of the Stille reaction 
 
To be able to participate in the first step of this cycle, the Pd catalyst must be in its zero 
oxidation state, as Pd (0) (2).  This can be accomplished either by simply starting with Pd (0), 
for example as tetrakis(triphenylphophine)palladium(0)41, or by starting with the catalyst in 
the Pd (II) form (1) (as in the PdCl2(PPh3)2 complex for example) and reduce it to the active 
Pd (0) specie {Pd[P(Ph)3]2}.  During the first step of this catalytic cycle, a cis intermediate, 
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formed after the oxidative addition of the organohalide (3), rapidly isomerizes to the trans 
intermediate 4.  Intermediate 7 that is formed after transmetalation with the organostannane 
(5) finally produces the desired product (8) as well as the active Pd (0) species (2) after 
reductive elimination.50 What is important to note here is that the oxidative addition of the 
organohalide and the reductive elimination retain the stereochemical configuration of the 
respective reactants.  The active Pd (0) species was always assumed to exist but it was not 
until recently that it was observed direct experimentally when the Stille reaction was 
subjected to a special type of mass spectroscopy.48 As was mentioned earlier, the limitations 
of what functional group (R-group) can be used are very few, but their rate of transmetalation 
from the tin highly differ: alkynyl > alkenyl > aryl > allyl = benzyl > α-alkoxyalkyl > alkyl.  
The low reactivity of alkyl stannanes is a serious drawback of the Stille reaction but can be 
remedied by the use of strongly polar solvents, such as DMF. 
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2. Results and Discussion 
 
2.1 Identification of a novel scFv antibody 
 
Therapeutic antibodies have greatly revolutionized therapies for several cancer types.  
Although scFv antibody phage display has been used as a means to quickly select antibodies 
specific for certain cell types or tissues51, no antibody has been identified that is suitable for 
immunotherapy against pancreatic cancer.   
By direct panning of a naïve scFv phage library52 on freshly isolated pancreatic tumor cells, 
using the CBASTM method, the goal was to retrieve a scFv antibody that recognizes antigens 
on the surface of these cells.  The methods for the characterization of selected clones were 
done in an agreement with Marike Stassar, director project management at Affitech AS. 
   
2.1.1 Screening of the phage scFv display library 
 
Phage scFv display library 
The bacteria Escherichia coli (E. coli), strain XL-1-Blue were harvested, and the phagemids 
in those cells were packaged into phage particles with the helper phage (M13).  For the 
panning experiments, an IgD/IgM scFv naïve library was used that had been constructed from 
the pooled peripheral blood lymphocytes (PBL) of 6 healthy human donors and cloned into a 
phagemid display system based on the pSEX81 vector52 (Figure 12).  The phages expressing 
the scFv antibodies were screened by incubation and organic phase centrifugation of the 
tumor cells. The cell pellets were added to cultures of E. coli and incubated as described in 
Chapter 5.1.2. 
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Figure 12: The pSEX81 vector 
 
Culturing of cells 
When working with cells, wether keeping them in culture or isolating them for testing, it is 
important to use antiseptic techniques to avoid contamination of microorganisms.  Therefore, 
all solutions and equipment that were in contact with the cells were sterilized before use.  In 
addition, the antibiotics penicillin and streptomycin were added to the cell culture medium as 
an extra precaution to prevent bacterial growth.  All the cells that were used in this project 
(except PBL) were obtained from ATCC (The American Type Culture Collection).  
Descriptions of the cells, their origins, properties and culture conditions as well as their 
ATCC numbers, are described in the ATCC catalogue.53 
 
Antibody library screening, phage display 
PBL, LL-47 (human lung fibroblast cells, CCL-13553) and ASPC-1 (human pancreatic tumor 
cells, CRL-168253) cells were isolated/harvested and diluted to a concentration of 2 x 105 - 2 x 
106 cells/mL. 
To select tumor-specific scFv antibodies from the naïve scFv library two different strategies 
were applied, panning at 4 ˚C (strategy A) and at 37 ˚C (strategy B).  This was done in order 
to see which temperature would give a higher number of clones with affinity towards the 
pancreatic cancer cells. 
The precipitated phages were first panned against human PBL and LL-47 cells to remove 
non-tumor specific binders, and then used for a round of incubation with the pancreatic tumor 
cells, ASPC-1.  After panning on the pancreatic tumor cell line, an organic phage was used to 
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separate cell bound phages from those that did not bind.  A total of three rounds of selection 
were executed but no pre-panning was done during the last round of panning. 
After each round of panning, small samples of the culture were plated out on small agar plates 
containing antibiotics, so that only bacteria infected with the phages that bound to the tumor 
cells could grow.  Single bacteria form single colonies on the plates and therefore, if there is 
an increase in number of colonies after each round of panning, there is an increase in the 
number of tumor-cell bound phages.   
 
 
 
Figures 13a and 13b: Number of colonies after each round of panning 
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Figures 13a and 13b clearly show enrichment in the 3rd round of panning of the tumor specific 
scFv-containing phages.   This is true for both strategy A and B. 
After 3 rounds of selection, an ELISA assay was performed on the polyclonal products from 
A and B, obtained from the panning. This was done to test the affinity enrichment of phages 
with scFv binding towards the ASPC-1 cell line.  As shown in Figure 14, for both panning 
strategies, the signal increased dramatically for both strategies in round 3, indicating the 
success of the panning procedure in selecting tumor-specific scFv antibodies.     
 
 
Figure 14a and 14b: Polyclonal phage ELISA on tumor cells showing the enrichment of 
phages binding to the tumor cells. 
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Concomitantly, when ELISAs were performed using the PBL or LL-47 cell lines as the target 
there was no increase in the signal in round 3 with both panning strategies, showing  that the 
procedure does not inadvertently result in the generation of non-specific antibodies (Figures 
15a – 15c, only strategy A, ASPC-1 and PBL is shown). 
All three rounds of this panning procedure were performed twice.  First when the panning was 
performed, the cells were harvested using Trypsin-EDTA (ethylenediaminetetraacetic acid) to 
detach the cells from the cell culture flask.  Trypsin, being a protease, cleaves all the proteins 
that are present on the surface of the cells.  When the antigens are no longer present on the 
surface of the tumor cells, the scFv antibodies cannot bind to their target and the results of 
course showed no enrichment of tumor specific scFv fragments.  Therefore, the panning 
procedure was repeated, using only EDTA to harvest the cells. 
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Figures 15a – 15c: Polyclonal phage ELISA on cells after each of a total of 3 rounds of 
selection, showing a clear enrichment of phages binding to tumor cells. 
 
The same procedure of the polyclonal phage ELISA was done using maxisorp ELISA plates 
where the phages of each selection round were tested for binding to the blocking solution that 
was used during the phage selections (3 % BSA/PBS in 1 plate and 4 % milk/PBS in another 
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plate).  This was done to test for background binding of the phages.  Neither of the ELISA 
plates showed any binding of phages (data not shown). 
 
2.1.2 DNA-techniques 
 
From a biological view, a clone is a population of identical organisms that is derived from a 
single parental organism.  All the members of a single colony of bacterial cells that arise from 
one single cell grown on a petri plate are clones.54a 
Recombinant DNA technology involves manipulation of the genetic material by combining 
DNA from different hosts and thereby constructing a new combination that does not exist in 
nature.  Plasmids are naturally occurring, circular, independent replication elements that can 
replicate indefinitely outside the host chromosome.54b Those plasmids that are able to 
perpetuate themselves in E. coli, are often used when cloning DNA and serve as cloning 
vector.  The DNA fragment, containing the gene of interest, is inserted into artificial plasmids, 
which are carried into E. coli and propagated as part of the plasmid.27b   
Because the initial characterization of the polyclonal mixture obtained from the panning 
showed tumor cell line specific enrichment, the scFv DNA from this panning round was 
cloned into the vector pHOG2152 (Figure 16), and expressed in E. coli XL-1-Blue.  For this 
purpose the pSEX81-scFv plasmid was extracted from the transformed bacteria by a process 
called DNA preparation.  This was done by using maxi-preparation kit from QIAGEN which 
involves alkaline lysis to break the bacterial cells open and to release the plasmid DNA. The 
DNA is solidified by isopropanol precipitation and washed with 70 % ethanol to wash away 
any background salts.   
The scFv DNA fragments from A and B were “cut” out of the pSEX81 vector by digesting 
them with the enzymes NcoI and NotI, restriction enzymes that cut DNA at specific 
sequences (NcoI: C/CATGG, NotI: GC/GGCCGC) Using two restriction enzymes at the 
same time is called double digestion and is a commonly used method to manipulate the DNA 
when performing procedures like cloning. 
 Chapter 2. Results and Discussion 
 
The cloning vector (pHOG21) as shown
create a linear DNA molecule.  
added to the cut pHOG21 vector to 
molecule, containing the scFv DNA inserts, is finally covalently sealed
DNA ligase.27c  
Figure 16: The pHOG21 vector
To locate the scFv DNA fragment 
the samples were loaded onto an agarose gel and were then 
Agarose gel electrophoresis is a method that is used to determine the purity of DNA 
molecules and to separate DNA strands by size.  An electric field is used to move negatively 
charged DNA molecules uniformly through a gel matrix towards the positive electrode.  
speed of each fragment depends on its size, where smaller fragments travel faster than larger 
ones.  The pattern is then compa
size.  To locate the position of the DNA within the gel, the intercal
is added to the gel, which makes the DNA fluoresce when exposed to
light.27d  
A picture of the gel after electrophoresis is shown
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 in Figure 16, is cut with the restriction enzymes 
The scFv DNA that is cut out of the pSEX81 vector is
form a recombinant DNA circle.  The recombinant 
 with an enzyme called 
 
 
 
after digesting the pSEX vector with restriction enzymes, 
separated by electrophoresis
red to a pattern of a DNA marker with fragments of known 
ating dye ethidium bromide 
 ultraviolet (UV) 
 in Figure 17. 
to 
 then 
. 
The 
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Figure 17: A picture of the agarose gel after electrophoresis, showing the location of the 
scFv fragments 
 
The scFv fragments (ca 800 bp) were cut out of the gel and extracted by using gel extraction 
kit from QIAGEN.  This extraction kit can be used to extract and purify DNA of sizes from 
70 base pairs (bp) up to 10 kilo base pairs (kb) from agarose gels in TBE (Tris-borate-EDTA) 
buffer.  It consists of spin columns containing silica membrane that the DNA adsorbs to in the 
presence of high concentrations of salt.  Contaminants pass through the column and impurities 
are efficiently washed away.  The pure DNA is finally eluted with water.  A picture of the gel, 
after cutting out the scFv fragments is shown in Figure 18. 
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Figure 18: A picture of the gel, taken after the scFv fragments had been cut out 
 
After cloning the scFv into the pHOG21 cloning vector, the DNA was finally packaged into 
competent E. coli XL-1-Blue cells, where the scFv DNA was amplified. This is a technique 
called transformation and is used to introduce DNA into bacteria.  The bacterial cells (E. coli) 
that have been made competent (transiently permeable to DNA) through calcium chloride- 
and heat shock, are transfected with the cloning vector (pHOG21), containing the scFv DNA 
fragment.  Since pHOG21 carries genes for antibiotic resistance, those cells that have been 
successfully transfected can be selected by growing the bacteria in the presence of the 
antibiotic.  That way, only those cells that contain the recombinant plasmids will survive.27c 
The bacterial cultures were plated out on antibiotic-containing agar plates and single colonies 
were grown.  From these plates, 6000 scFv clones (1 colony contains 1 scFv clone), 3000 
from each panning strategy, were randomly picked with a robot (Q-Pix, Genetix) and 
expressed in a 96-deep well format, again using E. coli XL-1-Blue as a host.  The majority of 
genes are expressed as the proteins they encode. The process occurs in two steps: transcription 
(DNA → RNA) and translation (RNA → protein).54c IPTG (Isopropyl β-D-1-
thiogalactopyranoside) induces activity of the enzyme beta-galactosidase, which inhibits the 
lac repressor and therefore promotes lactose utilization.  In cloning experiments, the lacZ gene 
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is replaced with the gene of interest and then IPTG
supernatants from the deep well plates (containing the expressed scFv) were then tested using 
the Applied Biosystems 8200 Ce
 
2.1.3 Characterization of selected scFv clones
 
The 8200 Cellular detection system is used for fluorescence macro
enabled high throughput detection of tumor
to the surface of the pancreatic tumor cel
quantification of cellular fluorescence intensity.
1 cell line and did not show any 
shows an example of a photograph of the cells stained and visualized in the
Biosystems 8200 system.  
 
 ASPC-1   
Figure 19: An example of a tumor
visualized in the Applied Biosystems 8200 
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 is used to induce gene expression.
llular Detection System. 
 
-confocal screening.  It 
-specific scFv, identifying those clones 
l line, but not to the PBL and LL-
  Of the 6000 clones, 526 bound to the 
binding to the normal cell types, PBL and LL-47.  
LL-47     PBL 
-specific scFv that binds only to the ASPC
Cellular Detection system.
54a The 
that bound 
47, by direct 
ASPC-
Figure 19 
 Applied 
 
-1 cell line, 
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DNA fingerprinting – MvaI analysis 
The plasmid DNA of individual clones was extracted of the 526 positive clones using 
QIAGEN miniprep kit.  MvaI is a restriction enzyme that produces DNA fragments of 
different length by cutting the DNA at specific sequences (CCA/TGG) that occur often in the 
DNA, a process often called DNA fingerprinting.55a This method is used to exhibit a distinctly 
different banding pattern of different clones and it can therefore be seen how many of the 
clones have a different DNA sequence. 
At first, a DirectPrep 96 MiniPrep Kit (QIAGEN) was used, which enables one to do DNA 
extraction of 96 clones at the same time.  After digestion with the restriction enzyme MvaI 
and DNA analyzes, the results showed that during the extraction, the DNA of the clones had 
been mixed together.  The material in 1 well of the 96 well plate had mixed with the material 
in another well and so on.  This method was therefore considered useless for this work and 
despite of being time consuming it was decided to use the QIAprep Spin Miniprep Kit 
(QIAGEN) which involves extraction of the DNA from one clone at a time.  After 
purification, the clones were fingerprint analyzed with the use of MvaI.  After producing 
DNA fragments, they were separated by gel electrophoresis using a 10 % TBE gel, and finally 
the gel was stained with ethidium bromide and exposed to a UV light and a picture was taken.  
Figure 20 shows an example of few of the scFv fragments after MvaI digestion.   
 
 
DNA marker
Figure 20: A picture of a TBE gel after DNA fingerprinting the scFvs 
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In total 96 out of 526 clones turned out to be “different”, and of these 14 were from strategy A 
and 82 from strategy B.  The results were confirmed by DNA sequence analysis performed by 
GATC Biotech AG (Germany). 
These results show that over 85 % of the positive clones come from panning at 37 ˚C, so it 
seems like more tumor-specific scFv are obtained at this temperature than at 4˚C.  Since 
proteins normally internalize at 37 ˚C, these results support the hypothesis that the CBASTM 
method preferentially selects for antigen/antibody pairs that are internalizing,  
The 96 tumor-specific scFv were expressed in larger scale (10 mL) and their concentration 
was measured using Coomassie Brilliant Blue and the Bradford method.  The Bradford 
method is based on the fact that when bound to proteins, the color substance Coomassie 
Brilliant Blue has an absorption maximum shift from 465 nm to 595 nm.  Both hydrophobic 
and ionic interactions stabilize the anionic form of the dye, causing a visible color change.  
The concentration of an unknown protein sample is found using a standard curve that is based 
on a dilution series of BSA-solutions (bovine serum albumin).  The concentration of the scFv 
clones varied between 100 and 1000 µg/mL. 
The binding profile of the affinity purified scFv clones was characterized using fluorescence-
activated cell sorting (FACS).  For this, tumor cell lines of different tissue origin (Table 1) 
were incubated with the scFv.  Binding of the scFv was detected by incubation with a tag-
specific (c-Myc) antibody that is conjugated to a fluorescence label (FITC).  FACS is a 
powerful technique for analyzing large mixed populations of single cells.  The fluorescent 
signal is quantified and the cells that contain pre-selected characteristics (i.e. fluorescence 
intensity, size and viability) are separated from a mixed population.  A flow cytometer 
measures and analysis optical properties of single cells passing through a focused laser beam.  
When the cell passes through the beam, it disrupts and scatters the laser light, which is 
detected as a forward scattered and side scattered light.  Forward scattered light is related to 
cell size and side scattered light is an indicator of the cells granularity.  Together, these 
parameters can give an idea of how the cells have reacted to the stimulation.  In addition, the 
flow cytometer measures fluorescence parameters such as red or green fluorescence, which 
can be used when staining cells with FITC-labeled antibodies. 
The binding of the scFv antibodies to a various number of cancer cell lines of different origin 
as well as confirming their binding to the pancreatic cancer cell line was investigated, using 
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the ExpressPlus assay on the Guava EasyCyte PCA 96. Data acquisition and analysis was 
performed using the CytoSoftTM software 3.1.   
 
Name ATCC number Cell type 
ASPC-1 CRL-1682 Human pancreatic carcinoma 
LL-47 CCL-135 Human lung fibroblast 
SW480 CCL-228 Human colorectal adenocarcinoma 
Hs 38.T CRL-7826 Human ovary teratoma 
Du-145 HTB-81 Human prostate carcinoma 
A549 CCL-185 Human lung carcinoma 
Hs 578T HTB-126 Human breast carcinoma 
Table 1: Cell lines tested with FACS 
 
A representative scFv, designated B1-J21, that showed high binding to the pancreatic tumor 
cell line ASPC-1 was finally picked to serve as the scFv in the immunotoxin.  Figure 21 
shows the shift of the fluorescence signal to the right, following binding of the B1-J21 scFv to 
the tumor.  No activity was seen for the other cell lines.   
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Neg. control Hs 38.T A549 
SW480 ASPC-1 LL-47 
Hs 578T Du-145   
Figure 21: scFv B1-J21 only shows affinity towards the pancreatic cell line, ASPC-1 (the 
fluorescence signal shifts to the right). 
 
The pancreas carcinoma specific scFv B1-J21 was tested for internalization at Affitech AS.  
B1-J21 turned out not only to be positive for surface binding to the pancreatic cancer cell line, 
ASPC-1, but it was also quickly internalized into the cancer cell.  The binding and 
internalization property of the B1-J21 scFv, make this scFv highly promising as a delivery 
vehicle for a toxin in an immunotoxin complex directed towards pancreatic cancer cells. 
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2.2 Synthesis of the toxin 
 
2.2.1 Synthesis of 2,6-dichloro-9-(4-nitrobenzyl)-9H-purine (3a) 
 
2,6-Dichloropurine (2) was N-alkylated with 1-(chloromethyl)-4-nitrobenzene (8) (Scheme 8) 
in the presence of potassium carbonate, to give 2,6-dichloro-9-(4-nitrobenzyl)-9H-purine (3a) 
in 44 % yield.  The reaction conditions, solvent, temperature, time, etc., chosen for this 
reaction were the same as those used in earlier reported N-alkylation reactions of purine.56 
The N-7 benzylated isomer, 2,6-dichloro-7-(4-nitrobenzyl)-7H-purine (3b) was also formed, 
but as a minor isomer and was not isolated since it was not interesting for this project.  The 
ratio between the N-9 and N-7 benzylated isomers was 87 : 13 as judged by the crude 1H-
NMR.  The 1H shift of the benzylic protons (C-1’) was used to extinguish the N-9 isomer 
from the N-7 isomer.  The shift value for the protons in the former isomer is 5.52 while the 
value shifts downfield, to 5.61 ppm, for the protons in the N-7 isomer.  This high selectivity 
of the N-9 isomer is quite higher than reported earlier.57,58  
 
 
Scheme 8: Synthesis of 2,6-dichloro-9-(4-nitrobenzyl)-9H-purine (3a) 
 
Heteronuclear multiple quantum correlation (HMQC) and heteronuclear multiple bond 
correlation (HMBC) NMR spectroscopy supported the structure of compound 3a and hence 
the position of the p-substituted benzyl.  The 1H shift of the 2 methyl protons at 5.52 ppm 
served as a good starting point in the elucidation of the structure.  The methyl protons 
correlates to both C-4 (153.0 ppm) and C-8 (145.1 ppm) in the long range HMBC spectrum 
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(Spectrum 4, p. 74).  The H-8 (8.10 ppm) – C-8 (145.1 ppm) direct correlation was found 
from the HMQC spectrum (Spectrum 3, p. 74).  H-8 again correlates to C-4 at 153.0 ppm and 
C-5 at 130.6 ppm which confirms N-9 alkylation. 
 
2.2.2 Synthesis of N-{4-[(2,6-dichloro-9H-purin-9-yl)methyl]-phenyl}acet-
amide (4a), N-{4-[(2,6-dichloro-7H-purin-7-yl)methyl]phenyl}acetamide 
(4b) and N-(4-{[2-chloro-6-(dimethylamino)-9H-purin-9-yl]methyl}phenyl) 
acetamide (4c) 
 
 
Scheme 9: Synthesis of N-{4-[(2,6-dichloro-9H-purin-9-yl)methyl]phenyl}acetamide (4a) 
 
2,6-Dichloropurine (2) was N-alkylated with N-[4-(chloromethyl)phenyl]acetamide (9) 
(Scheme 2), in the presence of potassium carbonate, to give N-{4-[(2,6-dichloro-9H-purin-9-
yl)methyl]-phenyl}acetamide (4a) in only 10 % yield.  The reaction conditions for this 
reaction were the same as for the reaction in Chapter 2.2.1.  The N-7 benzylated isomer, N-{4-
[(2,6-dichloro-7H-purin-7-yl)methyl]phenyl}acetamide (4b) was formed as a minor isomer, 
but since it was not interesting for this project, it was not isolated at that time. 
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In addition the by-product N-(4-{[2-chloro-6-(dimethylamino)-9H-purin-9-
yl]methyl}phenyl)acetamide (4c) was isolated in 23 % yield.  At first it was difficult to figure 
out what had happened and to identify the by-product since the 1H-NMR only showed two 
very broad and small peaks around 3.4 ppm (Spectrum 11, p. 81).  Naturally occurring 
nitrogen has a spin of 1 and instead of splitting neighboring protons, it tends to broaden 
them.55b Later, when the spectra was taken at 60 ˚C, the two peaks became one, more narrow, 
singlet and integrated to 6 corresponding to the 6 H’s on the dimethyl groups, attached to the 
amino group in the 6-position.  It was only after analyzing the MS spectra, which showed 
346/344 as the molecular ion instead of 339/337/335, that the structure of the product 4c 
became clear.  There has been a nucleophilic substitution of the chlorine in the 6-postion by a 
dimethyl amine (Me2NH) group from the DMF, which seems to have decomposed.  The 
reason why it was so difficult to discover what had happened is because of a hindered rotation 
of the N-C6 bond (Figure 22).  
 
Figure 22: Hindered rotation of N-C6 
 
The MS spectra shows that the structure still contains one –Cl group and it is well known that 
in halopurines that contain more than one halogen, the order of replacement is 6 > 8 > 2.40 
Selective substitution of 2,6-dichloropurines in the purine 6-position is therefore easily 
achieved when reacted with halogen nucleophiles57 and it was therefore assumed that the 
Me2NH group sits in the purine 6-position and not in the 2-position.  The unusually low ppm 
value for C-5 in the 13C-NMR (Spectrum 13, p. 82) also indicates this.  NMR signal for a 
carbon that is orto to an Ar-Cl group is usually ca 16 ppm higher than for a carbon that is 
ortho to an Ar-NH2 group.59   
The reason for the bad condition of the DMF is long- and insufficient storage.  It had been 
distilled 14 months prior to use and had repeatedly been standing at room temperature, for 
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several hours at a time.  The decomposition of this polar, aprotic solvent is catalyzed by either 
acidic or basic materials.  If DMF is allowed to stand for several hours and not handled and 
stored sufficiently, that is dried with molecular sieves and stored under dry nitrogen, it easily 
decomposes, even at room temperature.  Therefore, the solvent decomposed to Me2NH and 
carbon monoxide (CO) and caused a nucleophilic aromatic substitution in the 6-position.60 
The separation of the 3 different products, 4a, 4b and 4c was done with repeated flash 
chromatography.  During the flash chromatography, a mixture of acetone, hexane and ethyl 
acetate (EtOAc) were first used as eluent but it turned out to be very difficult to separate the 
compounds 4a and 4c.  At first they were in fact thought to be the two N-9 and N-7 isomers 
but the NMR of the two compounds showed no difference.  Later the solvent system was 
changed to methanol (MeOH) and dichloromethane and then a good separation was obtained. 
What is interesting to note here is that during the flash chromatography, the order of when the 
products came out of the column changed when the solvent system was changed.  When using 
a mixture of acetone, hexane and EtOAc, in different concentration, the products came out of 
the column in following order; 4a, 4b and 4c, but when the solvent system was changed to 
methanol and dichloromethane the order changed to 4c, 4a and finally 4b. 
The reaction was later repeated, using freshly distilled DMF, and the N-9 benzylated product 
was isolated in 34 % yield.  The N-7 benzylated isomer, N-{4-[(2,6-dichloro-7H-purin-7-
yl)methyl]phenyl}acetamide (4b) was again formed as a minor isomer.  According to the 1H-
NMR of the crude product mixture, the ratio of the N-9 : N-7 was 69 : 31.  This time, none of 
the by-product 4c was observed.  The benzylated isomers were separated by flash 
chromatography, using EtOAc : hexane (95 : 5) as eluent. 
Again, HMQC and HMBC NMR spectroscopy was used to differentiate between the N-9 and 
the N-7 isomers.  Correlations between the –CH2 protons and both C-8 and C-4 but not C-5 
supported the N-9 alkylated structure for compound 4a (Spectrum 7 and 8, p. 77).   
 
 
 
 Chapter 2. Results and Discussion  
47 
 
2.2.3 Synthesis of (E)-tributyl(styryl)stannane (10a) 
 
(E)-Tributyl(styryl)stannane (10a) was made via oxidative addition using 
azobis(isobutyronitrile) (AIBN) as a catalyst61 (Scheme 10).  Repeated attempts to purify 10a 
failed since the product always decomposed on the silica gel, both from Merck as well as 
from SdS.  The crude product was therefore used without further purifications and was first 
considered to be 65 % pure.  Later it was discovered that the crude product was only 35 % 
pure.  This was judged by 1H-NMR spectroscopy of the crude product as well as comparing 
the spectroscopic data to those reported earlier.62 The ratio between the trans (10a) and cis 
(10b) isomers formed was considered to be 65 : 35 and the ratio between the trans (10a) 
isomer and the Bu3Sn-SnBu3 dimer (10c) was 44 : 56.  The two trans protons in the 1H-NMR 
spectra (Spectrum 14, p. 84) have the same shift value and therefore only a singlet is observed 
and not a doublet as expected.  This is also in agreement to what has been reported earlier.62 
The coupling constants of the two cis protons (J = 13.7) in compound 10b confirm that these 
are the signals for the cis product and not trans, since the coupling constants for the trans 
product are usually somewhat higher (≈ 19 Hz).55b None of the starting material 11 was 
observed as judged by the crude 1H-NMR. 
 
 
Scheme 10: Synthesis of (E)-tributyl(styryl)stannane (10a) 
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2.2.4 Synthesis of (E)-N-{4-[(2-chloro-6-trans-styryl-9H-purin-9-yl) 
methyl]phenyl}acetamide (5) and N-{4-[(2-Chloro-6-methoxy-9H-purin-9-
yl)methyl]phenyl}acetamide (12) 
 
N-{4-[(2,6-dichloro-9H-purin-9-yl)methyl]phenyl}acetamide (4a) was subjected to Stille 
coupling to the styryl organotin reagent 10a in the presence of 5 mol % Pd(0) catalyst  to give 
the product, (E)-N-{4-[(2-chloro-6-styryl-9H-purin-9-yl)methyl]phenyl}acetamide (5), in 41 
% yield, based on the amount of compound 4a used.  
 
Scheme 11: Synthesis of (E)-N-{4-[(2-chloro-6-trans-styryl-9H-purin-9-yl)methyl] 
phenyl}acetamide (5) 
 
The co-product, Bu3SnCl (10c), formed in the Stille reaction was separated from the crude 
product in Scheme 11, by converting it into the tin fluoride (Bu3SnF).  This was done by 
treating the crude product with an alcoholic solution of potassium fluoride.  Bu3SnCl formed 
in the Stille coupling is a highly lipophilic compound, but is retained on the column during 
purification via flash chromatography.  Because of this, the co-product comes out of the 
column in small amounts over a long time together with the product and is therefore often a 
contaminant in the product.  By converting Bu3SnCl to the more polar Bu3SnF, the tin product 
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can be eluted out of the column without being contaminated with tin compound, which is 
retarded on the column.   
However, 6-chloropurines readily undergo substitution reactions when treated with alcohols, 
in contrast to 2-chloropurines.57   When the crude product in Scheme 11 was treated with 
potassium fluoride in MeOH, formation of the corresponding 6-methoxypurine, N-{4-[(2-
chloro-6-methoxy-9H-purin-9-yl)methyl]phenyl}acetamide (12) was observed and isolated in 
48 % yield.  It seems that the chlorine in the 6-position of unreacted compound 4a has been 
attacked and substituted with the nucleophile (MeOH) (Scheme 12) and the high percentage 
of this unwanted product shows that there was a low conversion of compound 4a to the 
desired product 5 (Scheme 11). 
 
 
Scheme 12: Nucleophilic substitution 
 
It was discovered that the purity of the tin reagent had not been determined correctly, and 
instead of using 1.2 equivalents as is recommended in the literature56,57  only half of it, 0.6 
equivalents was used.  If the reaction had been carried out using the correct amount of the tin 
reagent, one could expect the yield of the product 5 to be as high as 82 % (2 x 41 %).   
The product 5 might also be prone to nucleophilic addition to the double bond, so called 
Michael addition63 (Scheme 13).  Although the product in Scheme 13 was not observed, with 
a “normal” high yield reaction, it might be better to remove the tributyltin chloride by 
dissolving it in acetonitrile and extract the Bu3SnCl with hexane57, instead of removing it by 
stirring the crude product with a saturated solution of potassium fluoride in MeOH.   
Unfortunately, there was not enough time to try this work-up procedure or to repeat the Stille 
reaction with the correct amount of the tin reagent 10a. 
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Scheme 13: Nucleophilic attack of MeOH 
 
Even though the amount of the styryltin reagent 10a needed in the reaction was mis-
calculated there is one thing that is worth noticing.  In the Stille reaction a 1 : 2 mixture of cis 
10b and trans 10a organotin reagent was employed but only the trans coupling product 5 was 
formed, as judged by looking at the coupling constants from the 1H-NMR of the crude 
product (J 16.0 Hz =CH and J 16.2 Hz HC= corresponding to trans).55b 
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2.2.5 Attempt to synthesize (E)-2-chloro-9-(4-nitrobenzyl)-6-trans-styryl-
9H-purine (6) 
 
Scheme 14: Synthesis of (E)-2-chloro-9-(4-nitrobenzyl)-6-trans-styryl-9H-purine (6) 
 
Several attempts were made to subject 2,6-dichloro-9-(4-nitrobenzyl)-9H-purine (3a) to Stille 
coupling with compound 10a (Scheme 14), but all attempts to isolate the wanted product 6, 
has failed.  On the other hand, 2-chloro-6-methoxy-9-(4-nitrobenzyl)-9H-purine (13) was 
isolated in 19 % yield.   
Again, a nucleophilic attack in the 6-position of compound 3a occurred like in synthesis of 
compound 5 only this time no conversion to the wanted product was observed.  After 
purification by flash chromatography 69 % of the starting material 3a was recovered.  Too 
little amount of the tin reagent is most likely the reason for these bad results in the Stille 
couplings.  The reactions should be repeated, using 1.2 equivalents of the tin reagent. 
Judging from the two Stille reactions seen in Schemes 11 and 14, it can be concluded that in 
order to synthesize the toxin, 7, it is better to subject compound 4a to Stille coupling than 
compound 3a.  Although the amount that was used of the tin reagent 10a in these two 
reactions was too little, the wanted product 5 was isolated in addition to the methoxy 
compound 12 when performing Stille reaction on compound 4a.  In contrast, none of the 
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wanted product 6 was detected when the Stille coupling was performed on compound 3a, only 
the methoxy compound 13, but this time in much lower yield.  The same reaction conditions 
and work-up procedures were tried out for these two reactions, and since 69 % of the starting 
material, 3a, was recovered in Scheme 14, the assumption can be made that the nitro group 
makes compound 3a less reactive than compound 4a.  Although the reason for this is not 
clear, it could be due to electronic difference between the two compounds.   
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3. Further Research 
 
The B1-J21 scFv antibody needs to be reacted to the SPDP linker and a free thiol group 
generated via reduction with DTT. 
In order to complete the synthesis of the toxin, the acetamide group of (E)-N-{4-[(2-chloro-6-
trans-styryl-9H-purin-9-yl)methyl]phenyl}acetamide (5) should be hydrolyzed to the amino 
group and reacted with the SDPD-linked B1-J21 scFv.  It would also be interesting to test 
different reaction conditions, different catalytic complex, higher temperature, etc. in order to 
couple the styryl group in the 6-position of compound 3a, and finally reduce the nitro group.  
The work-up conditions with acetonitrile and hexane after the coupling procedure should also 
be tested.  
With the correct amount of the tin reagent 10a and by removing the tributyltin chloride with 
acetonitrile and hexane, the Stille coupling of compound 4a is expected to give the coupling 
product 5 in a better yield and the toxin can be obtained by hydrolyzing the acetamide group. 
After coupling the toxin to the B1-J21 scFv, the immunotoxin should be tested for 
cytotoxicity to see if the toxin remains cytotoxic.  The complex should also be tested for 
antigen binding capacity in order to be sure that the B1-J21 scFv still has specific affinity 
towards pancreatic cancer cells and if the affinity is high enough to bind to its antigen on the 
surface of the cells.   
If these studies turn out to be positive, the biological stability of the immunotoxin complex 
should be tested, both in vitro and in vivo (mouse studies). 
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4. Conclusion 
 
A pancreatic carcinoma specific scFv antibody fragment, B1-J21, was identified and 
characterized by screening of a naïve phage scFv library.  A higher number of tumor specific 
clones were obtained when the panning procedure was done at 37 ˚C than at 4 ˚C.  These 
results, along with the fact that proteins normally internalize at 37 ˚C, support the hypothesis 
that the CBASTM method preferentially selects for internalizing antibodies.  The B1-J21 scFv 
did not bind to any of the normal cell lines that were included in the experiments, neither to 
any of the other cancer cell lines that were tested; colon-, ovary-, lung-, prostate- and breast 
cancer cells.  Another positive aspect of this clone is that after binding to its antigen on the 
surface of the tumor cell, it is quickly internalized.  This is an important requirement in order 
for the scFv to act as a delivery vehicle for the toxin in an immunotoxin complex. 
2,6-Dichloro-9-(4-nitrobenzyl)-9H-purine (3a) was synthesized via N-alkylation of 2,6-
dichloropurine, with higher N-9 selectivity  than previously reported.  Compound 3a was 
subjected to Stille coupling with the styryl organotin reagent 10a, without success in purifying 
the wanted product 6.  The most likely explanation for this is that only half the molar 
equivalents of the tin reagent was used, compared to what is recommended in the literature.  
Another explanation might be that the nitro group para substituted on the benzyl in the purine 
9-position somehow makes this compound less reactive to the cross-coupling reaction. 
2,6-Dichloropurine was also N-alkylated with compound 9 to give N-{4-[(2,6-dichloro-9H-
purin-9-yl)methyl]phenyl}acetamide (4a), isolated in 34 % yield.  Compound 4a was 
subjected to Stille coupling with the styryl tin reagent 10a and despite the fact that only half 
of the recommended amount was used, the product 5 was isolated in 41 % yield. 
When only one step was left in the synthesis of the toxin 7 (9-(4-aminobenzyl)-2-chloro-6-E-
styryl-9H-purine) the time intended for the work of this master’s degree came to an end. 
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5. Experimental 
 
5.1 Identification and characterization of a novel scFv antibody 
 
5.1.1 Isolation and culturing of cells 
 
The cells used in this project were grown in an incubator at 37 ˚C with 5 % CO2 and 
humidified air to stimulate an in vivo situation. 
 
Procedure for splitting of cells (LL-47 and ASPC-1): 
The 20 mL cell culture medium (ATCC catalogue53) was discarded from the cell culture flask 
and the monolayer was washed twice with 5 mL PBS (phosphate buffered saline).  Trypsin-
EDTA (4 mL) was added and the cells were incubated in a CO2 incubator for approx. for 5 
min and then transferred to a 50-mL tube with 10 mL cell culture medium.  The tube was 
centrifuged at 1600 rpm (revolutions per minute), for 5 min at 4 °C, the supernatant was 
discarded and the pellet was re-suspended in 5 mL cell culture medium.  The cell suspension 
was transferred to a new cell culture flask containing 20 mL fresh medium. 
The cells were splitted approximately twice a week for 3 weeks. 
 
Procedure for harvesting of cells (LL-47 and ASPC-1): 
The 20 mL cell culture medium was discarded and the monolayer washed twice with 5 mL 
PBS.  1 mM EDTA in PBS was added and the cells were incubated in a CO2 incubator for 
approx. 5 min. and then transferred to a 50-mL tube with 10 mL cell culture medium.  The 
tube was centrifuged at 1600 rpm, for 5 min at 4 °C, the supernatant was discarded and the 
pellet was re-suspended in 15 mL PBS (total volume).  A small sample, 20 µL, was diluted 1 : 
2 with Trypan Blue and the number of cells counted.  The rest of the cells were centrifuged at 
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1600 rpm, for 5 min at 4 °C and finally the pellet was re-suspended and diluted to an 
appropriate concentration.  The cells were kept on ice until used further.  
 
Isolation of peripheral blood lymphocytes (PBL) 
The lymphocytes were isolated from fresh human blood isolating the buffy coats by density 
gradient centrifugation on LymphoprepTM (Axis-Shield, Oslo, Norway).  The erythrocytes and 
plasma is removed and what is left of the blood, the lymphocytes, some platelets and 
monocytes, is called a buffy-coat.   
 
Procedure for isolating PBL: 
EDTA blood, 20 mL, was poured into a 50-mL tube and diluted 1 : 2 with PBS.  A volume of 
10 mL LymphoprepTM was added to 2 x 50-mL tubes and half of the diluted blood (20 mL) 
was pipetted carefully (with ca. 45 ˚ angle) into each LymphoprepTM containing tube, so that 
the blood stayed on top of the mixture.  The tubes were centrifuged at 2000 rpm, for 20 min at 
20 °C, with acceleration and brake set to zero.  The PBL cells, now in the middle layer, were 
pippetted out and pulled to one 50-mL tube and the tube was filled with PBS and centrifuged 
at 1600 rpm for 5 min at 4 °C.  After discarding the supernatant the cell pellet was re-
suspended in 10 mL PBS and then the tubes were filled again with PBS.  A small sample, 20 
µL, was diluted 1 : 2 with Trypan Blue and the number of cells was counted.  The rest of the 
cells were centrifuged at 1600 rpm for 5 min at 4 °C, discarding the supernatant.  Finally the 
cell pellet was re-suspended and diluted to an appropriate concentration.  The cells were kept 
on ice until used further. 
 
5.1.2 Cell based antibody selection (CBASTM) 
 
The panning procedure (see Chapter 1.3.1, p. 12) was performed at 4 ˚C (strategy A) and at 37 
˚C (strategy B).  Before incubating the phages displaying the scFv library sequences with the 
target tumor cells (ASPC-1), those components showing non-specific binding were removed 
by incubating the phage, approx. 3.8 x 1012 cfu (colony forming units) with the normal cell 
types, LL-47 and PBL.  A total of 3 rounds of panning were performed but in the 3rd and final 
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round, no pre-panning took place.  Instead the phages were only panned on the ASPC-1 
cancer cell line.  3 % BSA/PBS was used for washing in rounds 1 and 3 whereas 4 % 
milk/PBS was used in round 2. 
 
Procedure for CBASTM: 
One E. coli XL-1-Blue colony was inoculated in 5 mL 2YT medium containing 30 µg/mL 
tetracycline and incubated over-night, shaking at 37 °C.  A number of tubes, 6 x 1.5 mL, 8 x 2 
mL, and 6 x 4 mL, were coated with PBS/3 % BSA or 4 % milk/PBS over-night.  After 
harvesting ASPC-1 and LL-47 cells, they were diluted to a concentration of 2 x 105 - 2 x 106 
cells/mL in either 3 % BSA/PBS or 4 % milk/PBS.  PBL cells from a fresh EDTA blood were 
isolated and diluted to a concentration of 2 x 105 - 2 x 106 cells/mL with the same solution as 
the other cell lines. 
Pre-panning on LL-47 
Two 1.5-mL Eppendorf tubes containing 500 µL LL-47 each (ca. 5 x 105 cells) were 
incubated with 150 µL scFv phage library, rotating for 1 hour, at either 4 °C = A or 37 °C = 
B.  The tubes were centrifuged after the incubation (2200 rpm, 5 min, 4 °C) and the 
supernatant was collected on ice.  The cells were washed twice with 500 µL 3 % BSA/PBS or 
4 % milk/PBS and the supernatants were collected on ice.  Finally the three supernatants were 
combined (approx. 1.5 mL total → used for pre-panning on PBL). 
Pre-panning on PBL 
A total of 500 µL PBL cells (ca. 5 x 105 cells) were incubated with 1.5 mL supernatant from 
pre-panning on LL-47 and rotated for 1 hour at either 4 °C or 37 °C.  The tubes were 
centrifuged after the incubation (2200 rpm, 5 min, 4 °C) and the supernatant was collected on 
ice.  The cells were washed twice with 500 µL 3 % BSA/PBS or 4 % milk/PBS and the 
supernatants were collected on ice.  Finally the three supernatants were combined (approx. 3 
mL total → used for panning on ASPC-1). 
The E. coli XL-1-Blue bacterium was inoculated at this stage in order for the bacterium to be 
in a log phase at the time of infection. 
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Panning on ASPC-1 
Two 4-mL cryo-tubes (Nunc, Roskilde, Denmark), each containing 500 µL (ca. 1 x 106) 
tumor cells, were incubated with the supernatant from pre-panning on PBL and rotated at 4 ˚C 
for 1 hour. 
Washing-step using organic phase centrifugation 
Each panning tube was divided over two 2-mL Eppendorf tubes and centrifuged at 2200 rpm 
for 5 min at 4 °C, discarding the supernatant.  The cells were combined by re-suspension in 1 
mL PBS/0.4 % BSA and centrifuged again.  After repeating the washing step, the cells were 
re-suspended in 300 µL PBS/0.4 % BSA, and 2 x 150 µL were laid on top of 2 x 300 µL 
organic phase [dibutyl phthalate : cyclohexane (9 : 1)].  The tubes were centrifuged at 9700 
rpm for 10 min at room termperature (rt) and then snap-freezed with liquid nitrogen.  The 
bottom of the tubes was cut off and the phage pellet was collected into a fresh 1.5-mL tube 
and put on ice until infection 
Infection of E. coli XL-1-Blue 
Approximately 2 hours before infection, an over-night culture of XL-1-Blue was inoculated at 
the calculated OD600 = 0.05 in preheated medium.  After 2 hours, a 10 mL culture (OD600 = 
0.3 – 0.4) was infected with each phage-fraction (A) and (B).  Each culture was incubated at 
60 rpm for 30 min at 37 °C, and then for another 30 min at 37 °C, 220 rpm. 
Plating 
A total of 100 µL per infection was plated on small SOBTAG plates (SOB medium containing 
30 µg/mL tetracycline, 50 µg/mL ampicillin and 100 mM glucose) at 3 dilutions (diluted in 
2YT medium); 1:104, 1:106 and 1:109.  The remaining culture was centrifuged at 4000 rpm for 
5 min and re-suspended in 1 mL 2YT medium.  2 x 500 µL was plated on 2 large rectangular 
SOBTAG plates, 500 µL on each plate.  This was done for both strategy A and B and all plates 
were incubated over-night at 37 °C. 
Counting colonies 
The following day, the colonies from the small plates were counted. 
Bacterial infection 
The large plates were scraped into two 50-mL tubes (one for each strategy) using 35 mL 2YT 
medium and the OD600 was measured.  The cell pellets were added to 10 mL cultures of XL-
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1-Blue in log phase and incubated at 60 rpm for 30 min at 37 °C, and then again for another 
30 min at 220 rpm.  A total of 2 x 50 mL 2YTTAG medium was inoculated to OD600 = 0.025 
and the culture was incubated at 37 °C, 220 rpm, to OD600 = 0.1 (ca 2-3 hours).  The 
M13KO7 helper phage was added and the culture was incubated for 15 min at 60 rpm and 
then for another 45 min at 220 rpm.  The culture was centrifuged at 3500 rpm for 10 min in 
50-mL tubes and the cell pellet was re-suspended in pre-warmed 50 mL 2YTAK, (2YT 
medium containing 100 µg/mL ampicillin and 50 µg/mL kanamycin) and incubated over-
night at 200 rpm, 30 °C.  The following day, the culture was spun down at 7500 rpm for 10 
min in 50-mL tubes and the supernatant was mixed with 1/5 volume PEG/NaCl (PEG = 
polyethylene glycol).  The mixture was incubated for 2 hours at 4 ˚C and centrifuged at 7500 
rpm for 10 min.  Finally the precipitated phages were re-suspended in 1 mL PBS.   
 
Polyclonal phage ELISA 
After 3 rounds of selection, an ELISA assay was performed on the polyclonal products from 
A and B, obtained from the panning. 
 
Procedure for polyclonal phage ELISA: 
A V-shaped 96-well plate (Greiner 651101) was coated with 3 % BSA/PBS, 100 µL per well, 
over-night at 4 ˚C.  The following day, PBL cells were isolated and diluted with 3 % 
BSA/PBS to a final concentration of a 1 x 106 cells/mL.  ASPC-1 and LL-47 cells were 
harvested and diluted to a concentration of a 1 x 106 cells/mL, with the same medium as the 
PBL cells.  The V-shaped plate was washed once with 100 µL PBS before adding 100 µL of 
ASPC-1, PBL and LL-47 cells to the wells, adding each cell line to total 22 wells.  The plate 
was incubated for 30 min at 4 °C and after the incubation, the cells were centrifuged at 2200 
rpm for 5 min at 4 °C.  The supernatant was poured off and the cell pellet was re-suspended 
on a mixer. 
The phages from each round of panning were diluted in 6 dilution series (1:10-1:106) in 3 % 
BSA/PBS and 70 µL of each dilution was added to each cell line [6 dilutions (10-106) of the 
scFv from each round was added to PBL, ASPC-1 and LL-47 cells, total 18 wells with each 
cell line.  4 wells of each cell line were used as controls].  After 1 hour incubation at 4 ˚C the 
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plate was centrifuged at 2200 rpm for 5 min at 4 °C.  The supernatant was poured off and 
after re-suspending the cell pellet, the plate was washed 3 times with 100 µL cold PBS.  A 
total of 100 µL of the α-fd antibody (diluted 1:1000 in 3 % BSA/PBS) was added to the 18 
scFv containing wells, while 100 µL of antibody αMHC class I (diluted 1:25 in 3 % 
BSA/PBS) and PBS was added to the 4 control wells (containing only cells and no scFv).  
The plate was incubated for 1 hour at 4 ˚C and centrifuged at 2200 rpm for 5 min at 4 °C.  
The supernatant was poured off and after re-suspending the cell pellet, the plate was washed 3 
times with 100 µL cold PBS.  A total of 100 µL of the secondary antibody goat-anti-rabbit 
HRP (horse radish peroxidase) (DakoCytomation, diluted 1:2000 in 3 % BSA/PBS) was 
added to the α-fd containing wells, while 100 µL of rabbit anti-mouse HRP antibody 
(DakoCytomation, diluted 1:2000 in 3 % BSA/PBS) was added to the control wells.  The 
plate was incubated for 1 hour at 4 ˚C and after centrifugation at 2200 rpm, for 5 min at 4 °C, 
the supernatant was poured off.  The cell pellet was re-suspended and the plate was washed 
with 100 µL cold PBS.  After 3 rounds of washing, the cell pellet was re-suspended in 100 µL 
ABTS (pre-warmed to 37 °C) and the plate was incubated for 10 min at rt.  Finally the plate 
was centrifuged, the supernatant transferred to an empty ELISA plate and the absorbance was 
measured at 405 nm. 
To test the background binding of phages the same procedure was done with 2 maxisorp 
ELISA plates (Nunc 430341), 1 coated with 3 % BSA/PBS and the other with 4 % milk/PBS.  
Those plates did not contain any cells.   
The same procedure was repeated for strategies A and B. 
 
5.1.3 Cloning and analysis 
 
Preparation of plasmid DNA (Maxi preparation) 
Maxi-prep was performed using a QIAGEN Plasmid Maxi Kit, according to the manual of the 
producer (QIAGEN) and the scFv DNA was extracted from the 3rd selection round of 
panning, both A and B.   
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Digestion of pSEX-scFv plasmids using the restriction enzymes NcoI and NotI 
The scFv DNA was digested with NcoI (New England BioLabs R0193L) and NotI (New 
England BioLabs R01892L), and the fragment that was cut out of the pSEX81 vector was 
ligated into the pHOG21 cloning vector. 
 
Agarose gel electrophoresis 
After cutting the scFv out of the pSEX81 vector, it was loaded onto an agarose gel, 
electrophorated, and cut out of the gel with the help of an UV light. 
 
Procedure for gel electrophoresis using 1 % agarosegel: 
To a total of 50 mL 1 % agarose in a 50-mL tube, 5 µL ethidium bromide was added.  The 
mixture was poured into a gel tray, inserting a cone (8 holes, to make sample-wells) at the top, 
and incubated for 30 min until the agarose was stiff.  The gel was then transferred to a 
electrophoresis tray, adding 1x TAE buffer (Tris-acetate-EDTA) and the cone was removed.  
To a 30 µL sample, containing the scFv DNA and the NcoI/NotI restriction enzymes, 6 µl of 
6x loading dye was added, and the reaction mix was applied onto the gel as well as a 1 kb and 
100 bp DNA markers.  After applying 90 voltage (V) for 1 hour the gel was removed from the 
tray and put under UV light. 
 
Gel extraction 
The extraction of the scFv from the gel was performed using QIAquick gel extraction kit 
(QIAGEN 28706) according to the manual of the producer. 
 
Procedure for digestion of pSEX-scFv plasmids with NcoI/NotI, followed by gel extraction of 
scFv fragment and estimation of DNA concentration: 
The scFv DNA from A and B were inoculated together with NcoI and NotI at 37 ˚C over-
night.  The following day, a 1 % agarose gel electrophoresis was run and after locating the 
scFv DNA on the gel with the help of a UV light, it was cut out and weighed.  Each DNA 
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fragment was then extracted from the gel, using the QUIAquick gel extraction kit and the 
concentration was estimated, using 1 % agarose gel electrophoresis and comparing the size of 
the fragments to a DNA marker containing 6x loading dye (Fermentas R0621). 
 
Ligation of DNA 
The scFv DNA was “glued” into the cloning vector pHOG21 with DNA ligase enzyme.  
 
Procedure for ligation: 
A ligation mix was made (10 µL total volume) containing the pHOG21 “dummy” (the vector 
without the scFv), the scFv fragment and DNA ligase enzyme (New England BioLabs, 
M0202L) and incubated at 16 ˚C for 1 hour.  A total of 2 µL room tempered cDNA 
(complementary DNA) was added to the ligation mix and the tube was immediately inverted 
for mixing, following an addition of 1.2 µL 3 M Na-acetate.  The tube was inverted again and 
100 % alcohol (26 µL) was added.  After inverting the tube 5 times, it was put on a vortex for 
10 seconds and incubated at rt for 2 min.  The tube was centrifuged at 14000 rpm for 5 min 
and the supernatant was discarded.  After adding 1 mL of 70 % alcohol to the pellet, the tube 
was centrifuged again at 14000 rpm for another 5 min, the supernatant was discarded and the 
tube centrifuged for additional 1 min.  After discarding the supernatant, the pellet was dried at 
rt and dissolved in 5 µL distilled water. 
 
Transformation of competent E. coli 
The pHOG21 cloning vector, containing the scFv DNA, was packaged into E. coli XL-1 Blue 
where the scFv DNA was amplified. 
 
Procedure for transformation: 
A total 950 µL SB medium in a 2-mL Eppendorf tube was preheated to 37 ºC.  
Electrocompetent XL-1 Blue cells were thawed on ice and reaction cuvettes were put on ice.  
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A total of 2 µL pHOG21 containing ligation mix was added to the cells and incubated on ice 
for 1 min.  The cells were then transferred to a chilled cuvette and electroporated.  
Immediately after, the cells were washed out of the cuvette, using the preheated SB medium, 
transferred to a new 2-mL tube and the tube was incubated at 1200 rpm, 37 ºC for 1 hour.  
The cell suspension was diluted (1:10, 1:100 and 1:1000) and 500 µL of each dilution was 
plated on big LBTAG plates (LB medium containing 30 µg/mL tetracycline, 50 µg/mL 
ampicillin and 100 mM glucose) using magnetic beads.  As a negative control, bacteria 
containing the empty plasmid were also plated.  All plates were incubated at 37 ºC over-night.  
This was done for both strategy A and for B. 
The following day, 3000 clones from each strategy were picked randomly using a Q-Pix robot 
(Genetix, New Milton, UK) and transferred to 16 x 384-well plates, where they were added 
LB medium, grown at 30 ˚C over-night and stored at -70 ˚C until tested. 
 
Deep well expression of the 6000 clones: 
The 6000 clones were expressed in a 96 deep-well format with IPTG as described.64   For 
each 384-well plate, 4 x 96 deep-well plates (ABgene, Epsom, UK) were needed, 72 plates in 
total. 
 
Procedure for deep well expression: 
Each deep well plate was filled with 100 µL LBGA (LB medium containing 100 mM glucose 
and 100 µg/mL ampicillin).  A total of 5 µL of each clone was transferred from the 384-well 
plate to a well in a 96-deep well plate, containing the 100 µL LBGA.  The plates were 
incubated over-night at 37 °C, 1100 rpm.  The following day the clones were re-inoculated by 
adding 6 µL of the over-night culture to a new 96-deep well plate, containing 100 µL LBA 
medium.  After incubating the plates for 4 hours at 37 °C, 1100 rpm, 12 µL LB medium 
containing 100 µg/mL ampicillin and 1mM IPTG was added to each well and the plates were 
incubated over-night at 30 °C, 1000 rpm.  The next day the expressions were frozen at -20 °C 
until they were tested further. 
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5.1.4 Analysis of protein expression 
 
8200 Cellular Detection System  
The material from the 96-deep well scFv expressions was tested with a cell ELISA assay in 
384-well plates to verify tumor cell binding.  The binding of the scFv to the cells was 
measured using the 8200 Cellular Detection System (Applied Biosystems).  The antibodies 
anti c-myc FMAT blue (Applied Biosystems) was used for PBL cells and combination of 
alexa fluor 647 goat anti mouse IgG (Invitrogen A21235) and anti c-myc (Invitrogen R950-
25) for ASPC-1 and LL-47 cells.   
 
Procedure for the ELISA assay using the 8200 Cellular Detection System: 
PBL cells were isolated and diluted in RPMI medium to a final concentration of a 7.5 x 105 
cells/mL.  ASPC-1 and LL-47 cells were harvested and diluted with their medium to a final 
concentration of a 7.5 x 105 cells/mL.  The scFv expressions were added to the wells, 10 µl of 
each clone to each well.  A total of 20 µL antistoff was added to the wells and finally 20 µL 
cell suspension was added to each sample and the plates were incubated at rt for 4 hours.  A 
picture of each sample was taken, showing weather the scFv bound to the cells or not, using 
the 8200 Cellular Detection System. 
 
Preparation of plasmid DNA (Mini preparation) 
Mini-prep was performed using QIAprep Spin Miniprep Kit, according to the manual of the 
producer (QIAGEN) and scFv DNA was extracted from those clones showing a positive 
binding to the ASPC-1 tumor cell line, but no binding to the other cell lines. 
 
Digestion of the scFv DNA with the restriction enzyme MvaI 
The scFv DNA was digested with MvaI (Fermentas ER0551), run on a gel electrophoresis 
using a 10 % TBE gel, and finally a picture of the gel was taken by exposing it to a UV light, 
showing which scFv clones were the same and how many of them were different.  
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Procedure for scFv DNA digestion with MvaI followed by gel electrophoresis using 10 % 
TBE gel: 
A 5 µL MvaI enzyme reaction mix was made, added to 5 µL of each scFv DNA and 
incubated at 37 ˚C over-night.  To each 10 µL sample, a 2 µL of 6x loading dye (Fermentas 
R0611) was added and the samples were loaded onto the gel.  A 1 kb DNA marker was 
diluted 1 : 10 with 1x TBE buffer and added 2 µL of 6x loading dye.  The samples were run 
on a 10 % criterion precast gel with TBE buffer, at 75 V for 1 hour and 45 min.  After that 
time, the gel was taken out of its tray and put into an empty tray containing 50 mL 1x TBE 
buffer and 5 µL ethidium bromide (5 mg/ml) and the gel was incubated for 30 min.  Picture of 
the gel was taken under the UV light. 
 
Expression (10 mL) of unique scFv clones 
Unique clones were expressed in a 10 mL volume, purified and their protein concentration 
was measured. 
 
Procedure for 10 mL expression and protein purification: 
Each clone was inoculated with 10 mL 2YT medium, containing 100 mM glucose and 100 
µg/mL ampicillin in a 50-mL Eppendorf tube and incubated at 37 °C, 250 rpm, over-night.  
The following day, the OD600 of each clone was measured.  Each clone was then re-inoculated 
with 10 mL 2YT medium, containing 10 mM glucose and 100 µg/mL ampicillin, to OD600 of 
0.1.  This was incubated at 37 ºC, 230 rpm, for 3-4 hours.  The 50-ml tubes were centrifuged 
at 4000 rpm for 15 min, rt, discarding the supernatant.  Each cell pellet was re-suspended in 
10 mL 2YT medium containing 100 µg/mL ampicillin and 0.1 mM IPTG.  Each expression 
was incubated at 30 ˚C, 200 rpm over-night.
 
 The following day, each tube was centrifuged at 
4000 rpm for 15 min at 4 ºC and the supernatants (medium) was collected and stored at 4 °C.
 
 
The cell pellet was re-suspended in 500 µL 50 mM Tris-HCl (pH 8) and the suspension was 
transferred to a 2-mL Eppendorf tube.  After adding 500 µL sucrose, 10 µL lysozyme and 10 
µL RNaseA, each tube was rotated on a rotating wheel for 1 hour at 4 ˚C.
 
 After that time, the 
tubes were centrifuged at 14000 rpm for 10 min at 4ºC and the supernatants for each clone, 
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both the periplasma obtained now and the medium that was stored at 4˚C, were combined.
 
 
The medium/periplasma solution was filtered through a 0,22 µm filter and to each 6 mL 
sample, 300 µL 1 M Tris-HCl (pH 7) and 2 mL 4 M NaCl was added.
 
Ni-NTA spin columns were placed in vacuum manifold and equilibrated with 600 µL start 
buffer (50 mM Tris-HCl pH 7 and 1 M NaCl).
.  
The samples were loaded onto the columns, 1 
column for each clone, washed once with 600 µL start buffer and twice with 600 µL wash 
buffer (50 mM Tris-HCl pH 7, 1 M NaCl and 20 mM imidazole).   Each column was placed 
in an Eppendorf tube and 400 µL elution buffer (50 mM Tris-HCl pH 7, 1 M NaCl and 250 
mM imidazole) was added to the column and together they were centrifuged at 2500 rpm for 
2 min at rt for elution.
 
 Eluted fractions were finally dialyzed in a Slide-A-Lyzer Dialysis 
Casette  against 5 liters PBS over-night at 4 ˚C.
 
 The following day, each clone was recovered 
from the dialyzing cassette and the protein concentration was measured using the Bradford 
method.
 
 
Procedure for measuring protein concentration: 
A dilution series of 12.5, 25, 50, 75, 100 and 125 µg/mL BSA was made by dissolving BSA 
in distilled water.  The unknown protein sample was diluted 1 : 5 and added to a 100 µL of 
each Bradford dilution.  The samples were incubated for 30 min at rt and the absorbance was 
measured at 595 nm before plotting the standard curve and calculate the unknown protein 
concentration. 
 
FACS/Flow cytometry analysis 
The binding of the scFv antibodies to a various number of cancer cell lines of different origin 
was tested by FACS using the ExpressPlus assay on the Guava EasyCyte PCA 96. Data 
acquisition and analysis was performed using CytoSoftTM software 3.1.   
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Procedure for flow cytometry analysis: 
Cells were harvested, diluted to a concentration of 5 x 106 cells/mL in PBS/2 % BSA/0.09 % 
NaN3 and aliquoted, 100 µL pr. well in a 96-well v-shaped plate (Greiner 651101).  The plate 
was centrifuged at 1600 rpm for 5 min at 4 ºC, discarding the supernatant.  50 µL of each 
scFv (diluted to a concentration of 10 µg/mL in /2 % BSA/0.09 % NaN3) was added to wells 
and the plate was incubated for 1 hour at 4 °C.  The cells were washed 3 times with 100 µL 
PBS/0.2 % BSA/ 0.09 % NaN3 before adding 50 µL of the antibody anti c-myc (5 µg/mL).  
The plate was incubated for 1 hour at 4 °C and then washed 3 times with 100 µL PBS/0.2 % 
BSA/ 0.09 % NaN3.  A total of 50 µL of the antibody anti mouse Ig-FITC (Dako F0479, 5 
µg/mL) was added to the wells, following 1 hour incubation at 4 °C.  After washing the cells 
3 times with 100 µL PBS/0.2 % BSA/ 0.09 % NaN3, fixation buffer (PBS/0.03 % 
formaldehyde, 100 µL) was added to wells and the cells were transferred to a u-shaped plate 
(Costar 3795). Additional 100 µL fixation buffer was added to each well and finally the 
samples were acquired on the Guava EasyCyte. 
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5.2. Toxin synthesis 
 
5.2.1 General 
 
Thin layer chromatoghraphy was used to determine Rf values and was performed on 60 F254 
silica coated aluminium plates from Merck.  Flash chromatography was done manually with 
silica gel from Merck (60, 40-63 µm).  Eluents used consisted of HPLC grade ethyl acetate, 
hexane and acetone. 
The 1H-NMR spectra were recorded at 500 MHz with a Bruker Avance DRX 500 instrument, 
at 300 MHz with a Bruker Avance DPX 300 instrument, or at 200 MHz with a Bruker Avance 
DPX 200 instrument.  The 13C-NMR spectra were recorded at 125, 75 or 50 MHz using 
instruments mentioned above.  Peak assignment in 1H-NMR and 13C-NMR is based on 
information obtained from HMQC and HMBC spectroscopy. 
DMF was distilled from BaO.  Nitrogen for inert atmosphere work was used as delivered 
from AGA. 
Mass spectra were recorded at 70 eV ionizing voltage with a VG Prospec sector instrument 
(Fissions Instruments) and are presented as m/z (% rel. int.).   
Melting points were determined with a Büchi B-545 melting point apparatus and are 
uncorrected. 
All other reagents were commercially available and used as received.   
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5.2.2 2,6-Dichloro-9-(4-nitrobenzyl)-9H-purine (3a)  
 
A mixture of 2,6-dichloropurine (2) (0.95 g, 5.0 mmol, 1.0 equiv.) and potassium carbonate 
(2.1 g, 15 mmol, 3.0 equiv.) in dry DMF (20 mL) was stirred at ambient temperature under N2 
atmosphere.  After 30 min. 4-nitrobenzyl chloride (8) (1.7 g, 10 mmol, 2.0 equiv.) was added 
and the resulting mixture was stirred for 20 hours, filtered and evaporated in vacuo.  The 
crude product was subjected to flash chromatography eluting with EtOAc : hexane (80 : 20) 
followed by acetone : EtOAc : hexane (20 : 15 : 65).  2,6-Dichloro-7-(4-nitrobenzyl)-7H-
purine (3b) was not isolated. 
 
2 4
5
8
2'
3'
4'
5'
1' 6'
7'
N
N N
N
Cl
NO2
Cl
3a
6
 
Yield 698 mg (44 %) orange solid. 
M.p. 171 – 174 ˚C. 
1H-NMR (CDCl3, 300 MHz): δ 5.52 (s, 2H, CH2), 7.46 (d, J 8.7 Hz, 2H, H-3’ and H-7’), 8.10 
(s, 1H, H-8), 8.24 (d, J 8.7 Hz, 2H, H-4’ and H-6’). 
13C-NMR (CDCl3, 75 MHz): δ 47.1 (C-1’), 124.5 (C-4’ and C-6’), 128.7 (C-3’ and C-7’), 
130.6 (C-5), 140.9 (C-2’), 145.1 (C-8), 148.2 (C-5’), 152.3 (C-2/C-6), 153.0 (C-4), 153.6 (C-
2/C-6). 
MS (EI): 327/325/323 (11/65/100, M+), 290 (11), 288 (33), 201 (8), 136 (31), 106 (39). 
HR-MS: Found: 322.9973. Calculated value for C12H7Cl2N5O2: 322.9977. 
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Spectrum 1: 1H-NMR of 2,6-dichloro-9-(4-nitrobenzyl)-9H-purine (3a) 
 
Spectrum 2: 13C-NMR of 2,6-dichloro-9-(4-nitrobenzyl)-9H-purine (3a) 
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Spectrum 3: HMQC of 2,6-dichloro-9-(4-nitrobenzyl)-9H-purine (3a) 
 
Spectrum 4: HMBC of 2,6-dichloro-9-(4-nitrobenzyl)-9H-purine (3a) 
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5.2.3 N-{4-[(2,6-Dichloro-9H-purin-9-yl)methyl]phenyl} acetamide (4a), N-
{4-[(2,6-dichloro-7H-purin-7-yl)methyl]phenyl}acetamide (4b) and N-(4-
{[2-chloro-6-(dimethylamino)-9H-purin-9-yl]methyl}phenyl)acetamide (4c) 
 
A mixture of 2,6-dichloropurine (2) (0.95 g, 5.0 mmol, 1.0 equiv.) and potassium carbonate 
(2.1 g, 15 mmol, 3.0 equiv.) in dry DMF (20 mL) was stirred at ambient temperature under N2 
atmosphere.  After 30 min. 4-acetamidebenzyl chloride (9) (1.8 g, 10 mmol, 2.0 eq) was 
added and the resulting mixture was stirred for 20 hours, filtered and evaporated in vacuo.  
The products were separated by flash chromatography using EtOAc : hexane (95 : 5). 
 
N-{4-[(2,6-Dichloro-9H-purin-9-yl)methyl]phenyl}acetamide (4a) 
 
 
Yield 571 mg (34 %) colorless solid. 
M.p. 197 - 197 ˚C. 
1H-NMR (DMSO-d6, 300 MHz): δ 2.01 (s, 3H, CH3), 5.41 (s, 2H, CH2), 7.27 (d, J 8.5 Hz, 
2H, H-3’ and H-7’), 7.53 (d, J 8.5 Hz, 2H H-4’ and H-6’), 8.79 (s, 1H, H-8), 9.95 (s, 1H, NH). 
13C-NMR (DMSO-d6, 75 MHz): δ 23.9 (C-9’), 46.8 (C-1’), 119.1 (C-4’ and C-6’), 128.2 (C-
3’ and C-7’), 129.9 (C-2’), 130.5 (C-5), 139.2 (C-5’), 148.3 (C-8), 149.7 (C-2/C-6), 151.1 (C-
2/C-6), 153.3 (C-4), 168.3 (C-8’). 
MS (EI): 339/337/335 (4/23/35, M+), 295 (13), 293 (20), 148 (31), 106 (100). 
HR-MS: Found: 335.0340. Calculated value for C14H11Cl2N5O: 335.0341. 
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Spectrum 5: 1H-NMR of N-{4-[(2,6-dichloro-9H-purin-9-yl)methyl]phenyl}acetamide (4a) 
 
Spectrum 6: 13C-NMR of N-{4-[(2,6-dichloro-9H-purin-9-yl)methyl]phenyl}acetamide (4a) 
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Spectrum 7: HMQC of N-{4-[(2,6-dichloro-9H-purin-9-yl)methyl]phenyl}acetamide (4a) 
 
Spectrum 8: HMBC of N-{4-[(2,6-dichloro-9H-purin-9-yl)methyl]phenyl}acetamide (4a) 
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N-{4-[(2,6-Dichloro-7H-purin-7-yl)methyl]phenyl}acetamide (4b) 
 
 
Yield 243 mg (15 %) colorless solid. 
M.p. 182 - 184 ˚C. 
1H-NMR (DMSO-d6, 300 MHz): δ 2.0 (s, 3H, CH3), 5.65 (s, 2H, CH2), 7.15 (d, J 8.6 Hz, 2H, 
H-3’ and H-7’), 7.53 (d. J 8,5 Hz, 2H, H-4’ and H-6’), 9.0 (s, 1H, H-8), 9.95 (s, 1H, NH). 
13C-NMR (DMSO-d6, 75 MHz): δ 23.9 (C-9’), 49.3 (C-1’), 119.1 (C-4’ and C-6’), 121.8 (C-
5), 127.2 (C-3’ and C7’), 130.6 (C-2’), 139.0 (C-5’), 143.2 (C-2/C-6), 151.0 (C-2/C-6), 152.7 
(C-8), 163.4 (C-4), 168.3 (C-8’). 
MS (EI): 339/337/335 (3/18/27, M+), 295 (7), 293 (10), 148 (41), 106 (100). 
HR-MS: Found: 335.0334. Calculated value for C14H11Cl2N5O: 335.0341 
 
 
 Chapter 5. Experimental  
79 
 
 
Spectrum 9: 1H-NMR of N-{4-[(2,6-dichloro-7H-purin-7-yl)methyl]phenyl}acetamide (4b) 
 
Spectrum 10: 13C-NMR of N-{4-[(2,6-dichloro-7H-purin-7-yl)methyl]phenyl}acetamide (4b) 
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N-(4-{[2-Chloro-6-(dimethylamino)-9H-purin-9-yl]methyl}phenyl) 
acetamide (4c) 
 
 
Yield 397 mg (23 %) colorless solid. 
1H-NMR (DMSO-d6, 60 ˚C, 500 MHz): δ 2.01 (s, 3H, CH3), 3.44 (s, 6H, (CH3)2), 5.26 (s, 
2H, CH2), 7.20 (d, J 8.5 Hz, 2H, H-3’ and H-7’), 7.52 (d, J 8.5 Hz, 2H, H-4’ and H-6’), 8.16 
(s, 1H, H-8), 9.79 (s, 1H, NH). 
13C-NMR (DMSO-d6, 60 ˚C, 125 MHz): δ 23.6 (C-9’), 37.8 (C-1’’ and C-2’’), 45.7 (C-1’), 
118.1 (C-5), 119.1 (C-4’ and C-6’), 127.6 (C-3’ and C-7’), 130.7 (C-2’), 138.7 (C-5’), 139.8 
(C-8), 151.1 (C-4), 152.4 (C-2/C-6), 154.5 (C-2/C-6), 167.9 (C-8’). 
MS (EI): 346/344 (15/45, M+), 148 (38), 106 (100). 
HR-MS: Found: 344.1155. Calculated value for C14H11Cl2N5O: 344.1152 
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Spectrum 11: 1H-NMR of N-(4-{[2-chloro-6-(dimethylamino)-9H-purin-9-yl]methyl}phenyl) 
acetamide (4c) at 25˚C 
 
Spectrum 12: 1H-NMR of N-(4-{[2-chloro-6-(dimethylamino)-9H-purin-9-yl]methyl}phenyl) 
acetamide (4c) at 60˚C 
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Spectrum 13: 13C-NMR of N-(4-{[2-chloro-6-(dimethylamino)-9H-purin-9-yl]methyl}phenyl) 
acetamide (4c) at 60˚C 
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5.2.4 (E)-Tributyl(styryl)stannane (10a) 
 
A mixture of tributylstannane (4.0 mL, 15 mmol, 1.0 equiv.), phenylacetylene (11) (1.7 mL, 
15 mmol, 1.0 equiv.) and AIBN (0.10 g, 0.6 mmol, 0.04 equiv.) was heated slowly to 50 ˚C 
and maintained at that temperature for 24 hours, under N2 atmosphere.  The reaction mixture 
was cooled and a white precipitate was removed by filtration through a celite pad.  The 
solvent was evaporated in vacuo and the crude product 10a was used without further 
purification. The purity of the product was considered to be 35 % and it was considered to be 
composed of; (E)-tributyl(styryl)stannane (10a) : (Z)-tributyl(styryl)stannane (10b) : Bu3Sn-
SnBu3 (10c) (35 : 25 : 40) as judged by the crude 1H-NMR. 
 
 
Yield 5.74 g (35%) yellow liquid. 
1H-NMR (CDCl3, 200 MHz): δ 0.78-1.67 (m, 27H, 3 x Bu), 6.84 (s, 2H, =CH), 7.17-7.40 (m, 
5H, Ar). 
The 1H-NMR is in agreement with data reported earlier.61 
 
 
 
 Chapter 5. Experimental  
84 
 
 
Spectrum 14: 1H-NMR of (E)-tributyl(styryl)stannane (10a) 
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5.2.5 (E)-N-{4-[(2-Chloro-6-styryl-9H-purin-9-yl)methyl]phenyl}acetamide 
(5) and N-{4-[(2-chloro-6-methoxy-9H-purin-9-yl)methyl]phenyl} 
acetamide (12) 
 
[(2-Furyl)3P]4Pd was generated in situ by stirring a mixture of 
tris(dibenzylidenacetone)dipalladium (14 mg, 0.016 mmol) and tri(2-furyl)phosphine (26 mg, 
0.11 mmol) in DMF (2 mL) at ambient temperature for 15 min., under N2 atm.  Compound 4a 
(168 mg, 0.5 mmol) was dissolved in DMF (2mL) and stirred under N2 atmosphere for few 
minutes and then transferred to the flask containing the catalyst.  Finally the tin reagent, 10 
[350 mg, 0.3 mmol (35 % pure)] was added drop wise to the reaction mixture, which was 
stirred at 50˚C for 8 hours, under N2 atmosphere.  The resulting mixture was evaporated in 
vacuo and stirred with a saturated solution of potassium fluoride in methanol (15 mL) at 
ambient temperature for ca. 4 hours.  The residue was evaporated in vacuo with a small 
amount of silica gel (ca. 0.5 g.), added on top of a silica gel column and the products were 
isolated by flash chromatography, using EtOAc : hexane (66 : 33), followed by EtOAc : 
hexane (75 : 25), and finally pure EtOAc, as an eluent.  
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(E)-N-{4-[(2-Chloro-6-styryl-9H-purin-9-yl)methyl]phenyl}acetamide (5) 
 
 
Yield 83 mg (41 %) yellow wax. 
1H-NMR (CDCl3, 300 MHz): δ 2.13 (s, 3H, CH3), 5.32 (s, 2H, CH2), 7.22 – 7.51 (m, 8H, Ar), 
7.58 (d, J 16.2 Hz, 1H, CH=), 7.64 – 7.67 (m, 2H, Ar), 7.98 (s, 1H, H-8), 8.40 (d, J 16.0, 1H, 
CH=). 
13C-NMR (CDCl3, 75 MHz): δ 24.5 (C-9’), 47.0 (C-1’), 120.3 (C-1’’/C-2’’), 120.2, 121.3, 
128.1, 128.8, 128.9, 129.9 (CH in Ar), 130.2 (C-5), 135.6 and 138.4 (C2’ / C5’), 141.9 (C-
1’’/C-2’’), 144.3 (C-8), 154.4 (C-2), 155.8 (C-4), 168.5 (C-6). 
MS (EI): 407/405/403 (0.04/19/52, M+), 258 (19), 256 (57), 148 (48), 106 (100). 
HR-MS: Found: 403.1206. Calculated value for C22H18ClN5O: 403.1200. 
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Spectrum 15: 1H-NMR of (E)-N-{4-[(2-chloro-6-styryl-9H-purin-9-yl)methyl]phenyl}acetamide 
(5) 
 
Spectrum 16: 13C-NMR of (E)-N-{4-[(2-chloro-6-styryl-9H-purin-9-yl)methyl]phenyl}acetamide 
(5) 
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N-{4-[(2-Chloro-6-methoxy-9H-purin-9-yl)methyl]phenyl}acetamide (12) 
 
 
Yield 80 mg (48 %,) off-white solid. 
M.p. 203 - 204 ˚C. 
1H-NMR (DMSO-d6, 300 MHz): δ 2.00 (s, 3H, CH3), 4.09 (s, 3H, -OCH3), 5.35 (s, 2H, CH2), 
7.22 (d, J 8.6 Hz, 2H, H-3’ and H-7’), 7.52 (d, J 8.6 Hz, 2H, H-4’ and H-6’), 8.48 (s, H8), 
9.94 (s, 1H, NH). 
13C-NMR (DMSO-d6, 75 MHz): δ 23.9 (C-9’), 46.3 (C-1’), 54.9 (C-1’’), 119.1 (C-4’ and C-
6’), 119.8 (C-5), 128.0 (C-3’ and C-7’), 130.5 (C-2’), 139.0 (C-5’), 144.5 (C-8), 151.4 (C-
2/C-6), 153.1 (C-4), 160.8 (C-2/C-6), 168.3 (C-8’). 
MS (EI): 333/331 (20/60, M+), 148 (73), 106 (100), 43 (17). 
HR-MS: Found: 331.0837. Calculated value for C15H14ClN5O2: 331.0836. 
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Spectrum 17: 1H-NMR of N-{4-[(2-chloro-6-methoxy-9H-purin-9-yl)methyl]phenyl}acetamide 
(12) 
 
 
Spectrum 18: 13C-NMR of N-{4-[(2-chloro-6-methoxy-9H-purin-9-yl)methyl]phenyl}acetamide 
(12) 
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5.2.6 Attempts to synthesize (E)-2-Chloro-9-(4-nitrobenzyl)-6-styryl-9H-
purine (6); synthesis of 2-chloro-6-methoxy-9-(4-nitrobenzyl)-9H-purine 
(13) 
 
[(2-Furyl)3P]4Pd was generated in situ by stirring a mixture of 
tris(dibenzylidenacetone)dipalladium (14 mg, 0.016 mmol) and tri(2-furyl)phosphine (26 mg, 
0.11 mmol) in DMF (2 mL) at ambient temperature for 15 min., under N2 atmosphere.  
Compound 3a (162 mg, 0.5 mmol) was dissolved in DMF (2 mL) and stirred under N2 
atmosphere for few minutes and then transferred to the flask containing the catalyst.  Finally 
the tin reagent, 10 (350 mg, 0.3 mmol (35% pure)) was added drop wise to the reaction 
mixture, which was stirred at 50 ˚C for 8 hours, under N2 atmosphere.  The resulting mixture 
was evaporated in vacuo and stirred with a saturated solution of potassium fluoride in 
methanol (15 mL) at ambient temperature for ca. 4 hours.  The residue was evaporated in 
vacuo with a small amount of silica gel (ca. 0.5 g.), added on top of a silica gel column and 
compound 13 was isolated by flash chromatography, using EtOAc : hexane (95 : 5), followed 
by pure EtOAc, as an eluent. 
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2-Chloro-6-methoxy-9-(4-nitrobenzyl)-9H-purine (13) 
 
 
Yield 30 mg (19 %), pale yellow solid. 
M.p. 205 - 206 ˚C. 
1H-NMR (CDCl3, 300 MHz): δ 4.20 (s, 3H, CH3), 5.47 (s, 2H, CH2), 7.41 (d, J 8.7 Hz, 2H, 
H-3’ and H-7’), 7.88 (s, 1H, H-8), 8.21 (d, J 8.7 Hz, 2H, H-4’ and H-6’).    
13C-NMR (DMSO-d6, 75 MHz): δ 46.0 (C-1’), 55.0 (C-1’’), 119.9 (C-5), 123.9 (C-4’ and C-
6’), 128.5 (C-3’ and C7’), 143.6 (C-2’), 144.6 (C-8), 147.1 (C-5’), 151.6 (C-2/C-6), 153.1 (C-
4), 160.9 (C-2/C-6). 
MS (EI): 321/319 (34/100, M+), 284 (23), 106 (24). 
HR-MS: Found: 319.0475. Calculated value for C13H10ClN5O3: 319.0472. 
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Spectrum 19: 1H-NMR of 2-chloro-6-methoxy-9-(4-nitrobenzyl)-9H-purine (13) 
 
 
Spectrum 20: 13C-NMR of 2-chloro-6-methoxy-9-(4-nitrobenzyl)-9H-purine (13) 
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